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ABSTRACT 
Estrogen deficiency increases the risk of a wide variety of pathological conditions including 
osteoporosis. Morbidity from osteoporosis is substantial in both men and women. Hormone 
replacement therapy (HRT, including estrogens) is associated with side-effects such as increased 
risk of breast cancer, stroke and deep venous thrombosis, and agents that can maintain the 
benefit of estrogen but avoid the risks are therefore needed. Testosterone is the precursor 
molecule of estradiol and its effects are mediated either via a direct activation of the androgen 
receptor (AR) or indirectly via aromatisation into estradiol and activation of estrogen receptor a 
(ERa) or ERß. The aim of this thesis was to compare the relative importance of and the 
interactions among AR, ERa, and ERß for bone metabolism in male and female mice. 
Male mice Orchidectomy resulted in a pronounced decrease in trabecular bone mineral 
density (BMD), which was completely prevented by estrogen treatment in wild type (WT) and 
ERß ' but not in ERa-' or ERa ' ß ' mice. This finding demonstrates that ERa is important while 
ERß is of no importance for the regulation of the trabecular BMD in male mice. Furthermore, 
in an additional study we showed that not only ERa activation but also a specific AR activation 
preserves the amount of trabecular bone in orchidectomized mice. Micro-computer 
tomography analyses demonstrated that ERa activation resulted in both preserved thickness 
and number of trabeculae, whereas AR activation only preserved the number but not the 
thickness of trabeculae. ERa activation increased serum levels of insulin-like growth factor I, 
which were positively correlated with all the cortical and trabecular bone parameters 
specifically preserved by ERa activation, suggesting that insulin-like growth factor I might 
mediate these skeletal effects of ERa activation. Thus, the in vivo bone-sparing effect of ERa 
activation is distinct from the bone-sparing effect of AR activation in adult male mice. 
Female mice By demonstrating that combined ER and AR activation resulted in a more 
pronounced effect on the trabecular bone than the single treatments in ovariectomized mice, 
we extended our previous findings that ERa, ERß as well as AR are of importance for the 
trabecular bone in female mice. Because the ER and the AR pathways are distinct from each 
other, a combined treatment of selective ER modulators and selective AR modulators might be 
beneficial in the treatment of osteoporosis. By investigating global estrogen-regulated gene 
transcription in ovariectomized mice, we found that ERß inhibits ERa-mediated gene 
transcription in the presence of ERa, whereas in the absence of ERa ERß can partially replace 
ERa. These findings indicate that one important physiological role of ERß is to modulate ERa-
mediated gene transcription, supporting a "Yin Yang" relationship between ERa and ERß in 
mice. 
In conclusion, ERa and AR-activation increases the amount of trabecular bone by distinct 
mechanisms while ERß is of no importance for the trabecular bone in male mice. In female 
mice, AR and ER-activation results in an additive effect on trabecular bone mass and ERß 
modulates ERa-mediated gene transcription in bone. 
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activation resulted in both preserved thickness and number of trabeculae, whereas AR 
activation only preserved the number but not the thickness of trabeculae. ERa activation 
increased serum levels of insulin-like growth factor I, which were positively correlated 
with all the cortical and trabecular bone parameters specifically preserved by ERa 
activation, suggesting that insulin-like growth factor I might mediate these skeletal effects 
of ERa activation. Thus, the in vivo bone-sparing effect of ERa activation is distinct from 
the bone-sparing effect of AR activation in adult male mice. 
Female mice By demonstrating that combined ER and AR activation resulted in a 
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of importance for the trabecular bone in female mice. Because the ER and the AR 
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and selective AR modulators might be beneficial in the treatment of osteoporosis. By 
investigating global estrogen-regulated gene transcription in ovariectomized mice, we 
found that ERß inhibits ERa-mediated gene transcription in the presence of ERa, 
whereas in the absence of ERa ERß can partially replace ERa. These findings indicate 
that one important physiological role of ERß is to modulate ERa-mediated gene 
transcription, supporting a "Yin Yang" relationship between ERa and ERß in mice. 
In conclusion, ERa and AR-activation increases the amount of trabecular bone by 
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Abbreviations 
3ß-HSD 3ß-hydroxysteroid dehydrogenase 
17ß-HSD 17ß-hydroxysteroid dehydrogenase 
aBMD areal bone mineral density 
AF-1/2 activation function 1/2 
ALP alkaline phosphatase 
ANGELS activators of nongenotropic estrogen-like signaling 
AP-1 activating protein 1 
AR androgen receptor 
ARE androgen responsive element 
BERKO estrogen receptor ß knockout (ERß/_) 
BMC bone mineral content 
BMD bone mineral density 
BMU basic multicellular unit 
BV/TV trabecular bone volume over total bone volume 
C/EBPß CCAAT/enhancer binding protein ß 
CBP CREB-binding protein 
CCD charged-coupled detector 
cDNA complementary DNA 
CRE cyclic AMP-response element 
CREB cAMP-response element binding protein 
CYP19 cytochrome p450 aromatase 
DBD DNA binding domain 
DERKO double estrogen receptor knockout (ERoc ' ERß" ~) 
DHEA dehydroepiandrosterone 
DHEA-S dehydroepiandrosterone sulfate 
DHT 5a-dihydrotestosterone 
DNA deoxyribonucleic acid 
DRIP vitamin D receptor-interacting protein 
DXA dual x-ray absorptiometry 
EGF epidermal growth factor 
ERa estrogen receptor a 
ERß estrogen receptor ß 
ERE estrogen responsive element 
ERK extracellular-signal regulated kinase 
ERKO estrogen receptor a knockout (ERcc7) 
EST expressed sequence tag 
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Estren estren-3a, 17ß-diol 
GPR30 G protein-coupled receptor 30 
IGF-I insulin-like growth factor-I 
IL interleukin 
JNK c-Jun N-terminal kinase 
KGF keratinocyte growth factor 
LBD ligand binding domain 
MAPK mitogen-activated protein kinase 
|iCT micro-computer tomography 
mRNA messenger RNA 
NCoR nuclear receptor corepressor 
NTD N-terminal domain 
Orx orchidectomy 
Ovx ovariectomy 
PCR polymerase chain reaction 
PI3K phosphatidylinositol 3-kinase 
PKA protein kinase A 
PKC protein kinase C 
pQCT peripheral quantitative computerised tomography 
PTH parathyroid hormone 
SARM selective androgen receptor modulator 
SERM selective estrogen receptor modulator 
SMRT silencing mediator of retinoid and thyroid receptors 
SNF sucrose non-fermenting 
SP-1 specificity protein 1 
SRC steroid receptor coactivators 
SWI mating type switching 
Tb.N. trabecular number 
Tb.Sp. trabecular separation 
Tb.Th. trabecular thickness 
TGFß transforming growth factor ß 
TNFa tumour necrosis factor a 
TRAP thyroid-hormone receptor associated protein 
vBMD volumetric bone mineral density 
WT wild type 
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Introduction 
General introduction 
Loss of bone mass along with microarchitectural deterioration leads to 
enhanced bone fragility and increased fracture risk — the bone disease 
known as osteoporosis (1). Osteoporosis affects both women and men, with a 
lifetime fracture risk of 40% in women and 20% in men, and the risk is likely 
to increase with longer life expectancy (2). After sex and age, the major risk 
factor for osteoporosis is estrogen deficiency. Estrogen replacement therapy 
is associated with side-effects such as b reast cancer, stroke and deep venous 
thrombosis. Therapeutic agents that can maintain the benefit of estrogen but 
avoid the risks are therefore needed. The development of such agents 
requires increased knowledge about the mechanism behind sex steroid 
action. 
Bone 
The function and structure of the skeleton 
Bone is spec ialized connective tissue which, together with cartilage, makes 
up the skeletal system. This tissue serves three functions: (i) mechanical, as 
support and site of muscle attachment for locomotion, (ii) protective, for vital 
organs and bone marrow, and (iii) metabolic, as a r eserve for ions, especially 
calcium and phosphate (3). The skeleton contains of two different types of 
bone, cortical and trabecular bone. They consist of the same cells and matrix 
elements, but there are structural and functional differences. Eighty to 
ninety percent of the volume of cortical bone is calcified, whereas only 15-
20% of the trabecular bone is calcified. This results in the major difference in 
function: cortical bone has mainly a mechanical and protective function 
whereas trabecular bone plays a more metabolic role, since more of its 
surface interfaces with soft tissue (3). The bone cells are: the osteoclasts, the 
bone resorbing cells; the osteoblasts, the bone forming cells responsible for 
production of the matrix constituents, and the osteocytes, originally 
osteoblasts entrapped in the matrix they produced (4-7). The extracellular 
matrix consists of collagen fibres, mainly type I, and noncollageneous 
proteins such as osteocalcin and alkaline phosphatase (ALP) (3). 
11 
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Structure of the long bones 
The long bones can be divided into 
three anatomical parts, the 
diaphysis, the metaphysis, and the 
epiphysis (3) (fig. 1). The diaphysis 
consists of cortical bone surrounding 
the bone marrow cavity. The outer 
part of the cortical bone is 
surrounded by the periosteum and 
the inner part by the endosteum. 
The epiphysis and the metaphysis 
consist of trabecular bone 
surrounded by a thin layer of 
cortical bone. They are separated by 
a layer of cartilage called the 
epiphyseal cartilage or the growth 
plate. 
Fig. 1. Schematic view of a longi­
tudinal section through a long bone. 
Bone formation 
Intramembranous ossification involves the replacement of sheet-like 
connective tissue membranes with bony tissue (3, 8). Bones formed in this 
manner include certain flat bones of the skull and some facial bones. The 
bones are first formed as connective tissue membranes. Osteoblasts migrate 
to the membranes and deposit bony matrix around them. Endochondral 
ossification involves the replacement of c artilage with bony tissue. Most of 
the bones of the skeleton, for instance the long bones, are formed in this 
manner. In this process, bones are first formed as cartilage models. The 
cartilage models become infiltrated with blood vessels and osteoblasts and a 
periosteum emerge. The osteoblasts form a collar of compact bone around the 
diaphysis and at the same time the cartilage in the centre of the diaphysis 
begins to disintegrate. Osteoblasts penetrate the disintegrating cartilage and 
replace it with spongy bone, which forms a primary ossification centre. 
Ossification continues from this centre toward the ends of t he bones. After 
spongy bone is formed in the diaphysis, osteoclasts break down the newly 
formed bone to open up the medullary cavity. The cartilage in the epiphysis 
continues to grow so the developing bone increases in length. Later, usually 
after birth, secondary ossification centres form in the epiphysis. When 
secondary ossification is complete, the cartilage is tot ally replaced by bone, 
Trabecular 
bone t 
Diaphysis/ 
Epiphysis 
Growth plate 
Metaphysis 
Cortical bone 
Periosteum 
Endosteum 
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except at the articular cartilage over the surface of the epiphysis and at the 
growth plate. 
Longitudinal growth 
Bones grow in length at the epiphyseal growth plate by a process that is 
similar to endochondral ossification. The cartilage in the region of the 
epiphyseal growth plate next to the epiphysis continues to grow by mitosis. 
The chondrocytes, in the region next to the diaphysis, begin to proliferate, 
and subsequently the chondrocytes differentiate and become hypertrophic. 
Following the mineralization process the chondrocytes undergo apoptosis (9, 
10). Osteoblasts move in and ossify the matrix to form bone. This process 
continues throughout childhood. At puberty, a growth spurt occurs, followed 
by a rapid decrease in growth velocity, attributable to growth plate 
maturation in long bones and spine, and leading to growth plate fusion and 
cessation of longitudinal growth (11, 12). Longitudinal bone growth is under 
the influence of a multitude of genetic and hormonal factors, growth factors, 
environment, and nutrition (13-16). 
Bone remodeling 
The bone mass increases until the age of 20-25, when it reaches its maximum 
value, peak bone mass (17-21). Once bone formation has ceased, peak bone 
mass is maintained by a process known as bone remodeling (22). This process 
is thought to enable the bone to respond and adapt to mechanical stress and 
also to repair damage to maintain strength. Old bone is removed (resorption) 
and new bone is created (formation). To maintain constant bone mass, bone 
formation and resorption have to be in perfect equilibrium. This is achieved 
by the coupling mechanism between the osteoblasts and the osteoclasts. 
However, after a certain age bone mass begins to decrease which can lead to 
osteoporosis and an increased risk of fracture. The bone remodeling process is 
cyclical with different phases taking place in basic multicellular units (BMUs) 
(23) (fig. 2). In the activation phase, preosteoclasts are stimulated and 
differentiate into active osteoclasts. During the subsequent resorption phase, 
the osteoclasts digest mineral matrix. In the intermediate phase, known as 
the reversal phase, resorption ends and osteoblasts migrate to the resorption 
site. During the formation phase, the osteoblasts produce matrix, which is 
subsequently mineralised. The whole remodeling cycle is u nder the control 
of cytokines, growth factors and hormones such as interleukin (IL)-l, TNFa, 
IL-6, TGFß, PTH, and vitamin D3 (22). In humans, the completion of one 
13 
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cycle takes 6-9 months and each year 3-4 million cycles are initiated, leading 
to complete regeneration of the skeleton approximately every ten years. 
Preosteoclasts Active 
osteoclasts Preosteoblasts Osteoblasts 
\ Mononuclear 
Activation Resorption Reversal Formation Mineralisation 
Fig. 2. The bone remodeling cycle. The cycle starts with activation of the 
preosteoclasts which, under the influence of cytokines and growth factors, 
differentiate and mature into active osteoclasts. In the resorption phase, the 
osteoclasts digest mineral matrix. This phase is followed by a reversal 
phase where the osteoclasts undergo apoptosis, and preosteoblasts 
become mature osteoblasts. Osteoblasts synthesize new bone matrix in the 
formation phase, and when the cavity is filled, osteoblast undergo apoptosis 
or turn into osteocytes or lining cells. The new bone becomes more densely 
mineralised for up to three years. 
Sexual dimorphism of the skeleton 
Adult men have greater bone mass than women, owing to greater bone 
volume, not greater volumetric bone mineral density (vBMD). At puberty, 
men develop bigger bone size than women, owing to increased periosteal 
apposition. In women, estrogens have an inhibitory effect on the periosteal 
bone formation. Furthermore, the epiphyseal closure is stimulated earlier by 
estrogens in women then in men. After puberty, the sexual dimorphism 
regarding bone size and bone mass is further enhanced, owing to increased 
periosteal apposition in males (24, 25). 
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Sex steroids and their receptors 
Synthesis and metabolism of sex steroids 
In premenopausal women, more than 95% of the estradiol in the circulatory 
system is derived from ovarian secretion. In young adult men, more than 
95% of serum testosterone is derived from testicular secretion (26). However, 
in postmenopausal women and elderly men, the gonadal secretion of sex 
steroids decreases and the main source of sex steroids is extragonadal 
conversion of C19 androgen precursors in the target tissue. The adrenal 
cortex and the gonads secrete large amounts of C19 androgens, mainly 
dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), and A4-
androstenedione (27, 28) (fig. 3). Although only weakly androgenic 
themselves, they are an important source of substrate for the extragonadal 
synthesis of potent sex steroids. In the periphery, CI9 androgens are 
converted into testosterone by 17ß-hydroxysteroid dehydrogenase (17ß-
HSD). In many target tissues, 5a-dihydrotestosterone (DHT), irreversibly 
formed from testosterone through the action of the enzyme 5a-reductase, is 
the main source of androgenic activity. Testosterone can also b e aromatised 
into estradiol by the enzyme cytochrome p450 aromatase (CYP19). 
Cholesterol 
I P-450scc 
Pregnenolone 
ICYP17 
17-Hydroxypregnenolone 
Steroid- \CYP17 
sulfotransferase * 3/i-HSD rvpi Q  
DHEA-S - » DHEA *Androstenedione —*• Estrone Steroid- I A  aromatase 
sulfatase 17ß-HSD\\ 17ß-HSD 
• I CYP19 
Testosterone a-^—£Estradiol 
5a-reductase\ 
Dihydrotestosterone 
Fig. 3. Sex steroid synthesis. Testosterone can be converted into 
dihydrotestosterone by 5a-reductase or it can be aromatised into estradiol 
by CYP19. 3ß-HSD: 3ß-hydroxysteroid dehydrogenase; 17ß-HSD: 17ß-
hydroxysteroid dehydrogenase; CYP19: cytochrome p450 (aromatase); 
DHEA: dehydroepiandrosterone; DHEA-S: dehydroepiandrosterone sulfate. 
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Structure of the sex steroid receptors 
Both the two estrogen receptors ERa and ERß as well as the androgen 
receptor AR belong to a superfamily of nuclear hormone receptors including 
those for other steroid hormones, thyroid hormone, vitamin D, and retinoic 
acid. The ERa was cloned in 1986 (29), AR in 1988 (30, 31), and ERß in 1996 
(32). Nuclear receptors are ligand-activated transcription factors that possess 
quite divergent N-terminal domains (NTDs) (A/B), high ly conserved DNA-
binding domains (DBDs) (C), a hinge region (D), and moderately conserved 
ligand-binding domains (LBDs) (E) (33) (fig. 4). The NTD encodes the ligand-
independent activation function 1, AF-1 (34). The LBD region is respon sible 
for the dimerisation of the protein, and this region also harbours AF-2, which 
is a complex region whose structure and function are governed by the 
binding of ligands (34). ERß appears to have no significant AF-1 activity, and 
thus depends entirely on the ligand-dependent AF-2 (35-37). 
AR 
ERa 
ERß 
<15% >50% 
A/B C 
<20% >95% I 
DNA 
Mr 
'Binding 
Domain 
20% 
60% 
Ligand £f3 
Binding 
Domain 
Fig. 4. Schematic representation of estrogen receptor (ER)a, ERß, and 
androgen receptor (AR). Nuclear receptors consist of five characteristic 
domains, A-F. Numbers represent percent of homology to ERa in the 
different domains. The DNA binding domain (C) is the most highly 
conserved domain between the nuclear receptors. AF-1/2: activation 
function 1/2. 
Mechanisms of action of sex steroids and their receptors 
Sex steroids are known to influence the expression of a wide range of genes 
by different mechanisms (38) (fig. 5). The most common, classic m eans of 
action is via a l igand-dependent activation of the specific receptor, but it is 
now well known that other mechanisms are also possible, s uch as l igand-
independent or DNA-binding-independent activation. Gene transcription 
16 
Introduction 
can also be activated by steroids via activation of a non-genomic signaling 
cascade. 
ER/AR and classic genomic activity 
Classically, these receptor proteins function as t ranscriptional factors in the 
nucleus when they are bound to their respective ligands (39). Hormone 
binding to the receptor activates the protein through phosphorylation. The 
receptor conformation is altered and chaperone proteins such as heat-shock 
protein 90 dissociate. The hormone-bound receptor then dimerises with 
another receptor, and the dimer binds to specific DNA sequences, i.e. 
estrogen or androgen responsive elements, ERE and ARE, respectively, 
present in the promoter of the responsive genes. Promoter-bound receptor 
dimers form a complex with coregulatory proteins that act coordinated to 
influence the transcription of the responsive genes (40, 41). Current 
estimates reveal that there are approximately 150 different coregulators that 
have been suggested to play a role in nuclear receptor actions in cells (42). 
Most characterized are coregulators of the steroid receptor coactivator (SRC)-
l/pl60 family; the acetyltransferases cyclic AMP-response element binding 
protein (CREB)-binding protein (CBP)/p300; the thyroid hormone receptor 
associated protein (TRAP)/vitamin D receptor-interacting protein 
(TRAP/DRIP) complex; the ATP-coupled chromatin remodeling SWI/SNF 
complex; and the complex of corepressor proteins including silencing 
mediator of retinoid and thyroid receptors (SMRT) and nuclear receptor 
corepressor (NCoR) (reviewed in (42, 43)). 
ER/AR and ligand-independent transcriptional activity 
The ER/AR function can also be modulated by extracellular signals in the 
absence of a hormone. This signal transduction is mediated via cross-talk 
between the receptors and growth factor receptors such as epidermal growth 
factor (EGF), keratinocyte growth factor (KGF), and insulin-like growth 
factor-I (IGF-I) receptors (44-50). Although the mechanism behind this 
modulation of gene and subsequent protein expression is not completely 
understood, the majority of evidence indicates that modification of the 
phosphorylation state of the ER/AR by cellular kinases such as mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 
serves as an important mechanism of ligand-independent activation (51-53). 
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ER/AR and non-classic transcriptional regulation 
ERs and AR have also been shown to modulate gene expression at alternative 
regulatory DNA sequences such as activating protein (AP)-l, specificity 
protein 1 (SP-1), variant cyclic AMP-response elements (CREs), Smad3 and 
upstream stimulatory factor sites, as well as other poorly defined non-
ERE/ARE sites (54-58). In these circumstances, ERs/AR do not function as 
the major transcription factor but rather are tethered to the specific promoter 
complex by its interaction with other DNA-bound transcription factors such 
as c-Jun and c-Fos, or with other coactivator proteins. Transcription of 
several genes important to growth factor signaling transduction pathways is 
regulated in this way. 
Sex steroids and non-genomic activity 
Sixty years ago it was reported that steroid hormones might have very rapid 
action on cells, too rapid to invoke transcriptional mechanisms (59). Binding 
sites for estrogen has been identified in the membrane of endometrial cells 
that trigger the induction of cyclic AMP (60). Binding sites for androgens 
have also b een found in plasma m embranes (61-63). Later studies have also 
argued for the presence of sex steroid receptors outside the nucleus that can 
mediate rapid signals originating from the membrane or in the cytoplasm 
(64). Recently, GPR30, a G protein-coupled receptor localised to the plasma 
membrane or the endoplasmic reticulum, has been found to be activated by 
estrogen (65-67). This nongenomic action or membrane-initiated steroid 
signaling occurs within minutes of the addition of the hormone. The 
membrane-initiated steroid signaling results in activation of conventional 
second messenger signal transduction cascades, including activation of 
protein kinase A (PKA), protein kinase C (PKC), cellular tyrosine kinases, 
MAPKs, PI3K and Akt-signaling enzymes and adaptors such as adenyl 
cyclase and Sch (68-70). 
Although it has become increasingly clear that sex steroids and their 
receptors are involved in a wide diversity of cellular pathways, it is important 
to bear in mind that the truth is even more complex, as the cellular pathways 
are often connected downstream of the signaling cascade. Furthermore, 
different pathways are important in different tissues and cell stages, and their 
significance regarding bone metabolism has not yet been clarified. 
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Fig. 5. Mechanisms of sex steroid signaling represented here by estrogen 
(E2) and estrogen receptor (ER). The effects of E2 are mediated through at 
least four pathways. 1) classic Ugand-dependent, E2-ER complexes bind to 
EREs in target promoters. 2) ligand-independent, for instance growth 
factors (GF) activate intracellular kinase pathways, leading to 
phosphorylation (P) and activation of ER at ERE-containing promoters in a 
ligand-independent manner. 3) ERE-independent, E2-ER complexes alter 
transcription of genes containing alternative response elements such as AP-
1 through association with other DNA-bound transcription factors (Jun/Fos). 
4) Non-genomic signaling, E2 activates a putative membrane-associated 
binding site, possibly a form of ER linked to intracellular signal transduction 
pathways that generate rapid tissue responses. 
ERß can function as a repressor of ERa 
Previous in vitro data has indicated that ERß can function as a dominant 
negative regulator of ERa activity. When complexed with estradiol, ERoc and 
ERß signal in opposite directions from an AP-1 site (71). Furthermore, 
transient transfection assays have demonstrated that ERß has the capacity to 
repress the transcriptional activity of ERa (36, 72). In vivo it has been 
demonstrated that female ERß inactivated mice have increased amounts of 
cortical hone and are partly protected against age-related trabecular bone loss 
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that normally occurs in old female wild type (WT) mice (73, 74). Therefore, 
one may speculate that ERß represses the bone-protection effects of estrogen 
mediated via ERa. 
Effects of sex steroids on the skeleton 
Until recently, androgens were assumed to be responsible for the pubertal 
growth spurt (75). However, it has now been established that the pubertal 
growth spurt of both sexes is dr iven primarily by estrogen (76). Estrogen is 
also responsible for the closure of the growth plate. In the few known 
examples of men who do not have the ability to aromatise estrogen from 
testosterone or with a disruption in the ERa gene, the growth plate is not 
properly closed and the longitudinal growth is therefore not interrupted (77-
79). Estrogen treatment closes the growth plate in men with a deficient 
aromatase gene but not in the man with disruption in the ERa gene (80, 81). 
Estrogen is also important to adult bone metabolism. The low levels of 
estrogen due to ovarian failure following menopause, associated with 
osteoporosis and higher rates of fractures are the clearest indications of th is. 
Estrogen has negative effects on bone resorption, although stimulatory 
effects on osteoblasts and bone formation have also been reported (82-84). 
More and more evidence has revealed that estrogen is important to both the 
female and male bone metabolisms. Adult men who cannot produce or 
respond to estrogen are osteopenic, and treatment with estrogen increases 
the bone mass of aromatase deficient men (78-80). Although men do note 
have the rapid phase of bone loss present at menopause in women, they still 
lose substantial amounts of bone as they age (85-88). Increased bone 
resorption in elderly men can be prevented by estrogen treatment (89, 90). 
The effects of sex steroids on the skeleton have been widely studied in 
rodents by use of castration, administration of ER antagonists, AR 
antagonists, aromatase inhibitors, selective estrogen receptor modulators 
(SERMs), and type II 5a-reductase inhibitors, and definitely also by use of 
transgenic mice. Gonadectomy reduces serum levels of androgens and 
estrogens, and this is associated with an increase in trabecular bone turnover, 
where bone resorption is more pronounced than bone formation, resulting in 
bone loss (91-95). Regarding the cortical bone, gonadectomy has a sexual 
dimorphic pattern. In males, orx decreases bone mass whereas in females the 
cortical bone mass in unaffected or increased after ovx (92, 96). Both 
aromatisable testosterone, the non-aromatisable DHT as well as estrogen 
have bone-sparing effects on the trabecular bone (93, 94, 97-100). It is clear 
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that both estrogen and androgen are important for the skeleton, although 
their relative significance has not been studied. 
Selective Estrogen and Androgen Receptor Modulators (SERMs/SARMs) 
In recent years, estrogen has been one of the most frequently prescribed 
drugs in the world. However, estrogen use has declined sharply in the wake 
of the early termination of the Women's Health Initiative (WHI) in 2002, 
once it became clear that the risks exceeded the benefits (101). SERMs are a 
new category of therapeutic agents available for the prevention and 
treatment of diseases such as osteoporosis and breast cancer. Unlike 
estrogens, which are uniformly agonistic, and antiestrogens, which are 
uniformly antagonistic, SERMs display an unusual tissue-selective 
pharmacology (102). They are agonistic in some tissues (bone and liver), 
antagonistic in other tissue (breast), and combined agonistic/antagonistic in 
the uterus. 
There is a great deal of hope that SERMs will mimic the essential benefits 
of estrogen for the bones at the same time as they will act as antiestrogens in 
the breast and uterus, thus avoiding the harmful effects of estrogen in these 
tissues. Most of the unique pharmacology of SERMs can be explained by 
three interactive mechanisms: (i) differential ER expression in a given target 
tissue, (ii) differential ER conformation on ligand binding, and (iii) 
differential expression and binding to the ER of coregulator proteins (103, 
104). Although the use of SERMs is widespread, there has not been a similar 
trend observed for androgen therapies. SARMs behave as partial agonists in 
androgenic tissues (prostate and seminal vesicle), and as full agonists in 
anabolic tissues (levator ani muscle). For osteoporosis indications, a SARM 
with anabolic activity in bone and possibly muscle, but with relatively little 
activity on sex-accessory tissues, would be desirable. The role of SARMs 
regarding osteoporosis is under investigation, but they are not yet used in 
clinical practice. 
Estren - activator of non-genotropic estrogen-like signaling (ANGELS)? 
Recently, a new synthetic compound, estren-3a,17ß-diol (estren), has been 
presented by the group of Dr. Manolagas (70, 100, 105). Estren has been 
suggested to be a mechanism-specific ligand of the ERs or the AR rather than 
being a tissue-specific ligand such as SERMs/SARMs. The term ANGELS has 
been coined for ER ligands that activate nongenotropic estrogen-like 
signaling, but that lack the ability to induce the classic transcriptional 
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activity of the ER. Estren is a four-ring synthetic steroid analogue 
prototypical compound of ANGELS propo sed to activate MAPKs and PI3K. 
This non-genomic pathway is suggested to be of importance for the 
trabecular BMD, whereas no effect of the compound has been found on the 
reproductive organs. 
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Aims of the thesis 
• To investigate the relative roles of sex steroid receptors in the regulation 
of the bone metabolism in male mice (papers I-II). 
• To investigate the effects of combined activation of both the ERs and the 
AR on the female rat skeleton (paper III). 
• To investigate the role of ERß and its possible interactions with ERa in 
global estrogen-regulated transcriptional activity (paper IV). 
• To further characterise the synthetic compound estren, regarding its 
tissue specificity and transcriptional activity (paper V). 
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Methodological considerations 
The methods used in this thesis are described in the Materials and Methods 
sections of the individual papers. A more general discussion of some of t he 
methods is presented below. 
Animal models 
Both rats and mice are used to study the effects of different treatments on the 
skeleton. Rats were initially most often used due to their larger size, but as a 
result of increased knowledge about transgenic mice, they are more 
commonly used today. Transgenic mice have one gene that is inactiva ted or 
overexpressed and the function of the specific gene can thereby be studied. 
One difference between the human and rodent skeleton is the closure of 
the growth plate, which takes place directly after puberty in humans. In 
rodents, the growth plate is never fully closed (106), but with increasing age, 
its characteristics stabilize and do not change significantly (107, 108). 
Furthermore, the coupling between the osteoblasts and osteoclasts which is 
crucial for the maintenance of the bone mass is independent of longitudinal 
growth and rodents may therefore be used as a model of adult human bone 
remodeling. 
ERa'" (ERKO), ERß+ (BERKO) and ERa' ERß"'" (DERKO) transgenic mice 
The generation of ERa ' ERß 7- (DERKO) is somewhat complex, since female 
ERoc-/- (ERKO), ERß-'- (BERKO) and male ERa'" (ERKO) mic e are infertile. 
Double heterozygous mice (ERa+/~ERß+/~) are mated, resulting in WT, ERa_/~ 
(ERKO), ERß - (BERKO) and ERa ERß A (DERKO) offsprings. This breed ing 
results in one ERa_/ ERß /_ (DERKO) pup of the right sex out of 32 offspring. 
The ERa_/" (ERKO) mice used in this thesis were not completely ERa-
inactivated. The mice express N-terminally modified transcripts generating a 
truncated ERa with remaining AF-2 activity, while AF-1 is a bsent (109). A 
second ERa_/ (ERKO) model lacking both AF-1 and AF-2 has been generated 
by the lab of Chambon (110). However, most skeletal phenotypes are 
identical for these two transgenic models, except as concerns female gonadal 
intact mice. 
Gonadectomy and hormonal treatment 
Surgical c astration, as induced by ovariectomy (ovx) in female rodents and 
orchidectomy (orx) in male rodents, represents the most frequently used 
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procedure for studying skeletal sex steroid action. Both ovx and orx 
dramatically reduce serum levels of testosterone and estrogen in rodents. 
However, since adrenal androgens can be transformed into estrogens after 
aromatisation, these procedures do not totally eliminate estrogen production. 
Gonadectomy is associated with a decrease in BMD, which corresponds to 
the decline in BMD seen in postmenopausal women and castrated men. 
The doses of 17ß-estradiol and DHT used in this thesis have been 
carefully chosen to correspond to normal serum levels of the hormones in 
the circulatory system. For 17ß-estradiol, this correspond to a preserved size 
of the uterus after ovx and for DHT treatment the dose chosen correspond to 
a preserved size of the seminal vesicles and the ventral prostate after orx. The 
dose of estren used in paper IV was chosen as being slightly lower than the 
dose used by Kousteni et al. (105). 
Measurements of bone parameters 
The methods mentioned below regarding measurements of bone parameters 
are illustrated in fig. 6. 
Fig. 6. Techniques for bone measurements. A) dual x-ray absorptiometry 
(DXA), B) peripheral quantitative computer tomography (pQCT), C) bone 
histomorphometry, and D) micro-computer tomography (pCT). DXA and 
bone histomorphometry are 2D techniques while pQCT and |jCT are 3D 
techniques. pQCT can measure both the cortical (upper image), and the 
trabecular bone (lower image). pCT is the technique with highest resolution, 
5 pm, which makes it possible to study separate trabeculae. 
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Histomorphometry 
Histomorphometry is the classic method used to study bone parameters. The 
bone of in terest is embedded in methacrylate resin, sectioned and analysed. 
In paper I, we measured bone structure parameters such as trabecular 
number (Tb.N.), trabecular thickness (Tb.Th.), trabecular separation (Tb.Sp.), 
and trabecular bone volume (BV/TV) using bone histomorphometry. 
Dual X-ray Absorptiometry (DXA) 
DXA is a non-invasive method widely used for determining BMD in both 
animals and humans. It has the advantage of being able to distinguish 
between soft tissue and bone, made possible by the fact that different tissues 
absorb X-ray to different extents. An emitted X-ray is divided into two 
different energy levels by a filter. Sensors detect the amount of radiation 
absorbed when each X-ray passes through the body. Using differen t pre-set 
thresholds, bone tissue may be either included or excluded from the 
measurement. One important disadvantage when using DXA for 
determination of bone mass is that the images produced are only two-
dimensional (2D). The DXA therefore only recognises changes in length and 
width and does not account for changes in the third dimension. This 
becomes a problem when examining growing animals with major skeletal 
changes in size. The areal bone mineral density (aBMD; g/cm 2) de termined 
by DXA should not be mistaken for true volumetric BMD (vBMD; g/cm3). In 
papers I and II, DXA measurements were performed with the Norland 
pDEXA Sabre (Norland, Fort Atkinson, Wisconsin, USA) and the Sabre 
Research software (v3.6 ) (73). In the in vivo measurements, one mouse was 
included in all the scans as an internal control, to avoid inter-scan variations. 
For in vivo measurements, medium resolution scans with the line spacing set 
at 500 pm wer e used, and for ex vivo measurements, high resolution scans 
were used (line spacing 100 pm). The inter-assay CV for the DXA 
measurements was less than 5%. 
Peripheral Quantitative Computerised Tomography (pQCT) 
pQCT is useful for the measurement of b one mass in animals and humans. 
However, the high radiation dose has limited its value in the clinical setting. 
pQCT is based on a rotating X-ray source, which moves to fixed positions 
around the specimen. A computer processes local attenuation data from each 
position and produces an image that represents a section through the 
specimen. The pQCT method admits measurements of cortical and trabecular 
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parameters of bone separately, which, in addition to measuring true vBMD, 
is an important advantage of this method. In papers I-III and V we measured 
two sections of the long bones; one in the mid-diaphysis, which consists only 
of cortical bone, and one in the metaphysis, consisting of both cortical and 
trabecular bone. Trabecular bone is defined as the inner 45% of the total 
cross-sectional area. The growth plate is used as a reference point in 
determining where to place the CT scan along the longitudinal axis. The 
pQCT measurements in this thesis were performed using the Stratec pQCT 
XCT Reasearch M (Version 4.5B,Norland, Fort Atkinson, Wisconsin, USA) 
operating at a resolution of 70 pm. The inter-assay CV for the pQCT 
measurements were less than 2%. 
Micro-Computer Tomography (pCT) 
While low bone mass is a ma jor component of fracture risk, the bone micro­
architecture, which defines the distribution of bone mass in three-
dimensional space, also contributes to the biomechanical integrity of the 
tissue, and therefore also to fracture risk. pCT scanning makes it possible to 
analyse the architecture of bones at the trabecular level non-destructively, 
both qualitatively by visual inspection of informative three dimensional (3D) 
images of the trabecular network, and quantitatively by calculation of 3D 
morphometric parameters (111, 112). Bone studies are well suited for the 
pCT technique owing to the high contrast between calcified and soft tissue. 
The resolution with this technique is 5 pm. 
The subject is placed on a rotating stage between an X-ray source and a 
charged-coupled detector (CCD) array. The spatial resolution of the image is 
primarily determined by the focal spot size of the X-ray source, the detector's 
array resolution, and the subject's position with respect to the source and 
detector. The imaging system provides a series of X-ray projections from a 
range of angles around the subject. Each projection represents the value of 
the X-ray attenuation line integral through the subject along the line from 
the X-ray source to the X-ray detector element. Imaging the subject at 
equiangular-spaced views over 180 degrees provides a complete set of 
projection data. Image reconstruction then creates a 2D image from the 
measured projection data and a 3D image is calculated by reconstructing and 
stacking individual 2D slices. Different algorithms are then used to calculate 
bone parameters such as bone volume/tissue volume (BV/TV), trabecular 
thickness (Tb.Th.), trabecular separation (Tb.Sp.), and trabecular number 
(Tb.N.). In papers II and III, we used a Skyscan 1072 scanner (Skyscan N.V., 
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Aartselaar, Belgium). The X-ray tube voltage was 50 kV and the scanning 
angular rotation was 185°. 
Mechanical testing 
Bone mass measurements can be used to indicate bone quality, but 
mechanical testing can add more relevant data. In papers I a nd II we used 
three-point bending. The bone is placed horizontally on two supports and a 
force is directed vertically to the midshaft of the bone until it breaks. During 
the initial part of th is process, the relationship between the force exerted on 
the material and the strain of the material will be linear. The slope of this 
linear relationship is the stiffness of the bone, also known as the elastic 
modulus or Young's modulus. Maximal stress is the maximum load under 
which the bone will break given in the unit force/area (Pascal). The force 
applied when the bone breaks is t he maximum load, which is give n in the 
unit Newton. Bone strength is not only dependent on the amount of mineral, 
but also on the external dimensions and the geometric arrangement of the 
mineralised mass. The area moment of inertia is a measurement of the radius 
from the cortex to the centre of the bone raised to the power of four. The 
importance of the area moment of inertia is illustrated by the greater cross-
sectional area in the cortical bone seen in males as compared with females, 
which contributes to the sex difference in bone strength. In papers I and II, 
the bones were analysed using the Mechanical Tester 8841 (Instron, Canton, 
Massachusetts, USA). T he bones were compressed at a constant speed of 2 
mm/min until failure. 
Analyses of gene expression 
GeneChip DNA microarray 
Microarray technology has opened new possibilities of large-scale mRNA 
expression profiling, where mRNA levels of many thousands of genes and 
expressed sequence tags (ESTs) can be analysed in one experiment, and 
requiring only a small amount of RNA. We used MG-U74Av2 Array 
(Affymetrix, Santa Clara, CA, USA) GeneChips. These GeneChip microarrays 
consist of small DNA probes, chemically synthesized at specific locations on a 
coated surface. Each gene is 25-mers and 16 different probes cover each gene. 
Each probe is synthesized to perfectly match the target gene (PM probe), and 
has a companion oligomer identical to the PM, except for a single base 
difference in a central position (the mismatch or MM probe). The MM probe 
serves as a control. The precise location where each probe is synthesized is 
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called a feature, and millions of features can be contained on one array. By 
extracting, amplifying, and labelling mRNAs from experimental samples and 
then hybridizing those prepared samples to the array, the amount of label 
can be monitored at each feature, enabling simultaneous relative 
quantification of the tens of thousands of different RNA transcripts, 
representing gene activity. The MG-U74Av2 Array consists of 6000 mouse 
genes and 6000 uncharacterised ESTs. 
In paper IV, RNA was prepared from a homogenate of the humerus or the 
liver and pooled into two pools per animal group. The RNA was transcribed 
into cDNA and further into biotin-labelled cRNA, which was fragmented 
before hybridisation to the GeneChip. After washing, the chip was scanned 
and the output files were analysed using the Affymetrix Micro Array Suite 
Version 4.0.1 software. To allow for comparison of gene expression, the 
GeneChips were scaled to an average intensity of 500. Estrogen-regulated 
genes were determined by calculating the average fold change between 
vehicle-treated and estrogen-treated samples. Within each genotype, 
comparisons were then made between the two vehicle-treated and the two 
estrogen-treated GeneChips, generating a total of 4 comparisons for each 
genotype. The criteria for genes to be regarded as regulated by estrogen were 
as follows: (i) the absolute call for the gene had to be present for all 
GeneChips and the average difference had to be above 200, (ii) at least three 
of the four comparisons had to be considered increased or decreased 
according to Affymetrix algorithms, and (iii) the average fold increase or 
decrease of the four comparisons was to be at least 2.0-fold. 
Real Time PCR 
The polymerase chain reaction (PCR) is a very sensitive method for the 
quantification of specific mRNAs. The method is based o n amplification of a 
cDNA sequence between a primer pair. In the real time PCR, the 
amplification can be followed over time and not only studied at the end of 
the reaction. A probe is desi gned to anneal between the two PCR primers. 
Two fluorescent dyes are attached to the 5 ' and the 3'ends of the probe, a 
reporter and a quencher. When both dyes are attached to the probe, the 
reporter dye emission is quenched, but when the Taq DNA polymerase 
cleaves the reporter from the probe during the extension cycle, the reporter 
dye emits its characteristic fluorescence. The intensity of the emitted 
fluorescence is proportional to the amount of amplicon produced. Only 
specific hybridisation generates a fluorescent signal. Two different mRNAs 
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can be measured simultaneously in the same reaction tube as long as t heir 
probes are labelled with different fluorescent dyes for the reporters. This 
allows the use of an internal standard. In paper IV, real time PCR was used 
on individual mice to confirm regulation of genes regulated in the pooled 
samples used for the microarray analysis. 
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Papers I and I! 
Sex steroids are important not only to the female skeleton, but also to the 
male skeleton. Experimental and clinical data support the importance of 
androgen and estrogen in the maintenance of normal BMD in males; 
however, the relative contribution of androgen versus estrogen in the 
regulation of the male skeleton is unclear. In order to investigate the relative 
importance of ERa and ERß in the regulation of adult bone metabolism in 
male mice, we used orx WT and ER-inactived (ERa7" (ERKO), ERß"7  
(BERKO) and ERa'ERß (DERKO)) male mice and treated them with 17ß-
estradiol or vehicle (paper I). Furthermore, to directly compare the effects of 
ER activation on bone with the effects of AR activation, orx WT and ERa7  
ERß7" mice were treated with 17ß-estradiol, the non-aromatisable androgen 
DHT, or vehicle (paper II). Previous studies have shown that ERa-
inactivated mice have raised levels of endogenous estrogen and testosterone, 
owing to disturbed feedback regulation (113, 114). This explains why we 
used orx mice in these studies. 
In gonadally intact male mice, no major differences were found regarding 
the amounts of trabecular bone. Orx decreased the total body aBMD and the 
trabecular vBMD to the same extent in all four genotypes. Treatment with 
17ß-estradiol prevented this orx-induced bone loss in WT and ERß7" 
(BERKO) mice, while no effects of 17ß-estradiol were found in ERa7" 
(ERKO) or ERa7 ERß7" (DERKO) mice. These pQCT measurement results 
were further confirmed by histomorphometric measurements and by pCT 
analyses, showing reductions in bone volume. Trabecular BMD was 
preserved in the gonadally intact ERa7 ERß7 (DERKO) mice in paper I, 
indicating that a testicular factor is of importance for the maintenance of 
trabecular bone mass. In paper II, we demonstrate that this testicular factor is 
androgens, which act on the AR. pQCT analyses showed that DHT treatment 
was as good as 17ß-estradiol treatment in preventing the orx-induced 
trabecular bone loss in WT mice. Furthermore, pCT analyses demonstrated 
that 17ß-estradiol treatment prevented the orx-induced reduction in bone 
volume as a result of both preserved number and preserved thickness of 
trabeculae in WT mice. DHT treatment only preserved the number of 
trabeculae, while trabeculae thickness was unaffected. Cortical bone 
parameters (BMC, area, and thickness) were increased after 17ß-estradiol 
31 
Results and comments 
treatment in orx ERa+/+ mice, 
whereas DHT treatment had no 
effects on the cortical bone. (fig. 7). 
It has been shown by others that 
estrogen treatment prevents orx-
induced bone loss, but we 
demonstrate here for the first time 
that this effect of estrogen in male 
mice takes place exclusively via th e 
ERa, while ERß is of no importance. 
DHT and 17ß-estradiol prevented 
orx-induced trabecular bone loss t o 
the same extent; however, upon 
closer examination of the bone a rchitecture, it became clear that AR and ER 
activation both preserved the number of trabeculae while the trabeculae 
thickness was exclusively preserved by ER activation. IGF-I serum levels 
were only affected by 17ß-estradiol and not by DHT, and association studies 
showed that parameters that were affected only by 17ß-estradiol and not by 
DHT (trabeculae thickness, cortical parameters and mechanical strength) did 
have a strong correlation to serum IGF-I levels. 
Previous in vitro studies have indicated that there is cross-reactivity 
between ERs and AR (70). However, we show that in vivo, the bone-sparing 
effect of 17ß-estradiol treatment is only via ERs and not via AR. Moreover, 
the AR activator DHT increased the amount of trabecular bone independent 
of ERs. 
Paper III 
As sho wn in paper II, both ERa activation and AR activation result in a 
bone-sparing effect, although in two distinct ways. One may therefore 
speculate that combined treatment with selective ER and AR modulators 
might be beneficial in the treatment of osteoporosis. In paper III, we 
investigated the effects of combined estrogen and androgen treatment on 
trabecular bone mass and longitudinal bone growth in ovx rats. 
As expected, 17ß-estradiol treatment prevented the ovx-induced 
trabecular bone loss as measured wit h both pQCT and |jCT. DHT t reatment 
also increased the bone mass as compared to that of vehicle-treated ovx rats, 
although it did not totally prevent ovx-induced bone loss. The com bination 
DHT Estrogen 
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AR ERa 
Trabecular 
Number 
Cortical 
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Trabecular Cortical 
Thickness Thickness 
Fig. 7. Differential effects on bone of 
estrogen receptor (ER)a and androgen 
receptor (AR) activation in adult male 
mice. 
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of 17ß-estradiol and DHT treatment was additive, resulting in higher 
trabecular bone mass with the combination of 17ß-estradiol and DHT 
treatment, than for 17ß-estradiol alone. |iCT analysis confirmed th e finding 
from paper II that 17ß-estradiol treatment increases both the thickness and 
number of trabeculae while DHT treatment only increases t he number of 
trabeculae. Furthermore, the combination of 17ß-estradiol and DHT 
treatment was additive regarding the number of trabeculae. 
The ovx-induced increase of th e length of the tibia was retard ed by 17ß-
estradiol, whereas DHT treatment did not have any effects on bone length. 
However, DHT in combination with 17ß-estradiol treatment counteracted 
the inhibitory effect of 17ß-estradiol alone on bone length. 17ß-Estradiol 
treatment reduced the width of the growth plate, which was associated with 
reductions in the number of proliferative and hypertrophic chondrocytes, 
and a reduction in the height of terminally differentiated hypertrophic 
chondrocytes. Addition of DHT to 17ß-estradiol treatment fully counteracted 
the 17ß-estradiol-induced reduction in height of hype rtrophic chondrocytes 
and partially counteracted the inhibitory effect on the number of 
proliferative chondrocytes, whereas it did not affect the number of 
hypertrophic chondrocytes. 
Paper III confirmed what has been shown before in male mice regarding 
the effects of 17ß-estradiol and DHT treatment alone on bone parameters. 
Furthermore, the paper also revealed that a combination of 17ß-estradiol and 
DHT treatment can have complex consequences. The paper shows that a 
combination of androgen and estrogen treatment can result in either additive 
or antagonistic effects depending on which bone parameter is studied. These 
findings suggest that combined treatment with selective ER modulators and 
selective AR modulators might be beneficial in the treatment of tr abecular 
bone loss in patients with osteoporosis. 
Paper IV 
Previous in vitro data indicates that ERß has the capacity to repress the 
transcriptional activity of ERa (36, 72). Furthermore, ERa and ERß signal in 
opposite directions from an AP-1 site when complexed wi th estradiol (71). 
The role of ERß as a dominant negative regulator of ERa has not been 
studied in vivo. In paper IV, using microarray analysis of the humerus and 
the liver, we investigated the interplay between ERa and ERß in a global 
sense. 
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When studying the humerus, 95% of the genes that were increased by 
estrogen in ovx WT mice were also increased by estrogen in ERß/_ (BERKO) 
mice. The average stimulatory effect of estrogen was 85% higher in ERß A 
(BERKO) mice th an in WT mice. When we looked at individual genes, we 
found that 80% of the genes were regulated more by estrogen in ERß7~ 
(BERKO) than in WT mice. Similar results were found when looking at the 
gene expression pattern in the liver. 
This study clearly shows that in the presence of E Ra, ERß reduces global 
estrogen-stimulated gene transcription in bone and liver, demonstrating that 
ERß is a global inhibitor of ERa-regulated gene transcription in mice. 
Paper V 
Development of ER ligands that retain the beneficial effects of estrogen in 
the targeted tissue, e.g. bone, but lack mitogenic and carcinogenic activity in 
breast and uterus, remains a major challenge. SERMs are ER ligands which, 
in some tissues, act like estrogens, but which block estrogen action in others. 
ANGELS, on the other hand, are mechanism-specific ligands of ER. Estren 
has been proposed to increase bone mass via non-genotropic estrogen-like 
signaling without affecting reproductive organs or classic transcription (105). 
In Paper V, estren was further characterised both in vivo (tissue specificity) 
and in vitro (transcriptional activity). 
In contrast to findings in a previous publication (105) estren treatment did 
have a clear effect on uterus weight in ovx mice compared to vehicle 
treatment. Thymus weight was decreased to the same extent by both 17ß-
estradiol and est ren treatment. Regarding bone parameters, e stren increased 
trabecular vBMD while there were no effects of estren treatment on any 
cortical bone parameter. A previous study has indicated that the effects of 
estren can be mediated via ERs an d AR with the same efficiency (70). To 
investigate whether estren can act via AR in vivo, we treated ovx ERa ' ERß 
/_ mice w ith estren. None of the effects of estren seen in ovx WT mice was 
found in these ER-inactivated mice. To further test the transcriptional 
activity of estren, h uman 293 kidney epithelial ERa- and ERß reporter cells 
were treated with estren. Estren displayed a full agonistic effect on the 
transcriptional activity, similar to the effects of 17ß-estradiol, although the 
affinity was lower. The results in this paper are in contrast with previous 
papers by Kousteni et al. (105). Here we show that estren actually has effects 
on the uterus, and that these effects are of the same order of magnitude as on 
trabecular vBMD. We also sho w that most of the effect of estren in ovx 
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female mice is mediated via ERs. Furthermore, estren has the capacity to 
exert classic ER mediated transcription. 
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Discussion 
Importance of sex steroids for the male skeleton 
Estrogen and testosterone have generally been considered the main sex 
steroids regulating bone metabolism in women and men, respectively. 
However, the discovery that several adult men who cannot produce or 
respond to estrogen are osteopenic, led to reconsideration of this notion (78-
80). Recent longitudinal studies indicate, moreover, that bioavailable 
estrogen correlates better than testosterone with loss of BMD in elderly men 
(115, 116). Studies in rodents have also shown that estrogen treatment 
prevents orx-induced bone loss in male rodents (93, 99, 117). Both aromatase 
deficiency (118, 119) and aromatase inhibition (120, 121) in rodents lead to 
decreases in the amounts of trabecular bone, which can be prevented by 
estrogen treatment (119, 122). Today, it is generally accepted that estrogen is 
of importance for the vBMD of trabecular bone in elderly men (123). Using 
ER-inactivated mice, we studied the importance of ERa and ERß for the 
maintenance of trabecular bone mass in male mice. In paper I, we clearly 
demonstrated that estrogen treatment only prevented orx-induced bone loss 
in presence of ERa, whereas presence of ERß was of no importance. Estrogen 
treatment totally prevented the orx-induced bone loss in WT and ERß ' , 
while it had no effects on the trabecular bone mass in ERa A or ERa ' ERß7" 
male mice. 
It has previously been shown that androgen treatment and activation of 
AR can prevent orx-induced bone loss (93, 97, 99). In paper I, we speculate 
that acquisition of trabecular bone mass in the ERa-inactivated mice was 
attributable to activation of the AR by androgens. It was further 
demonstrated in paper II, that AR activation by the non-aromatisable DHT 
actually prevents the orx-induced bone loss i n ERa-inactivated male mice. 
The quality of the bone should not only be regarded as determined by the 
trabecular BMD but also the micro-architecture of the bone (124). A c loser 
look at the micro-architecture by use of pCT analysis revealed that while 
ERa activation maintained both the trabeculae thickness and number, AR 
activation only maintained the trabecular mass in terms of increased number 
of trabeculae. Furthermore, cortical bone was only preserved after orx by 
estrogen treatment and not by DHT treatment. This regulation of cortical 
bone and trabecular thickness by estrogen correlated well with serum levels 
of IGF-I. We and others have recently shown that endocrine, liver-derived 
IGF-I is an important regulator of the amount of cortical bone and its 
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mechanical strength (125, 126). We therefore propose that activation of ERa 
but not AR results in raised serum levels of IGF-I, which, in turn, increases 
the amount of cortical bone and the trabecular thickness in male mice (fig. 
7). Together, ERa and AR are important for the maintenance of trabecular 
bone mass in male mice, whereas ERß is of no importance. 
Importance of sex steroids for the female skeleton 
It is well established that estrogen is an important regulator of the female 
skeleton. Postmenopausal osteoporosis is the most common form of 
osteoporosis. Ovx of rodents has long been used as a model for osteoporosis 
and is associat ed with dramatic decreases in trabecular bone, which can be 
prevented by estrogen treatment (92, 107, 127). Administration of a selective 
ER antagonist, ICI 182,780, induces trabecular loss in intact and estrogen-
repleted ovx female rats (128-130). Female mice with aromatase deficiency 
also have trabecular osteopenia, which can be prevented by estrogen 
treatment (98, 118, 119). Both estrogen acting on ERs and the non-
aromatisable androgen DHT acting on AR have bone-sparing effects in ovx 
rats (131-133). The notion that androgens are also important to the female 
skeleton is further supported by the fact that hyperandrogenic women have 
increased trabecular BMD (134). 
The combination of ER and AR activation in female rats was investigated 
in paper III. The study revealed that combined estrogen and androgen 
treatment results in an additive effect on the trabecular bone. As for the male 
mice, AR receptor stimulation increased the number of trabeculae, whereas 
ER stimulation increased both the number and thickness of trabeculae, 
which means that the additive effects of ER and AR activation on the bone 
mass were mainly attributable to an additive effect in terms of the number of 
trabeculae. These results contradict the findings in a previous study by 
Coxam et al. (133) where a combination of D HT and estrogen treatment did 
not alter the effects of single ER activation. This discrepancy between the 
two studies might be due to the difference in dose of DHT used or the 
difference in length between ovx and start of treatment. In the present study, 
treatment was initiated immediately after ovx, whereas in the previous study 
treatment only began after eight weeks. 
Estrogen and androgens are also known to be important to longitudinal 
growth. Ovx of female rats increases longitudinal growth (96, 129, 130, 135, 
136). In paper III, AR activation was found to counteract the inhibitory 
effect of ER activation on longitudinal bone growth, while it had no impact 
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on the estrogenic effect on the cortical bone. This disclosed that the results of 
combined AR and ER activation are highly complex, and depend on the 
parameters studied. 
ERß represses transcriptional activity of ERa 
In contrast to the findings in male mice, ERß is involved in the regulation of 
longitudinal growth in female mice. Female ERß '" mice have extended long 
bones, such that the normal sex differences regarding bone length is 
eliminated (73, 137). ERß is also important to the closure of the growth plate 
in female mice (138). Thus, ERß represses longitudinal growth in female 
mice and is suggested to be required for the sexual dimorphism of bone 
growth in mice. Both female and male ERa; mice have decreased 
longitudinal growth (137, 139, 140). Subsequently, ERa and ERß have 
opposing effects with regard to bone growth in female mice. Furthermore, 
female ERß ' mice have increased cortical bone dimensions and are partially 
protected against the age-related trabecular bone loss that normally affects 
WT mice (74). As early as 1997, Paech et al. (71) demonstrated in vitro thai 
ERa and ERß can exert opposing effects in the modulation of gene 
expression. Opposing effects of ERa and ERß have also been found in uterus 
and prostate (141, 142) and we have previously proposed that ERß also 
exhibits an inhibitory action on ERa in thymus involution and fat reduction 
(143). In paper IV, we show for the first time in wVothat ERß interacts with 
ERa on the transcriptional level. In the presence of ERa, ERß is not required 
for the gene transcription. However, when ERß is absent, the transcriptional 
activity of ERa is enhanced, demonstrating that ERß is mainly a regulator of 
the ERa activity. Both the stimulatory and the inhibitory effects of ERa on 
gene transcription were less p ronounced in the presence of ERß. The study 
was performed in humerus and similar regulation was also found in liver, 
demonstrating that this is a glo bal event and not specific to bone. However, 
in tissues such as prostate, ovary and lung tissue, i t is clear that ERß plays a 
major regulatory role in itself. It is important to take into account that ERß 
exhibits an inhibitory action on ERa-mediated gene expression and in many 
instances opposes the actions of ERa when developing SERMs with an ERß 
antagonist effect. The role of ERß antagonists might be to enhance the effects 
of ERa activation more than being direct independent effects on the 
transcriptional machinery. In conclusion, this is the first time it has been 
shown in vivo that ERß represses the ERa transcriptional activity. 
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Estren is not bone specific and it has transcriptional activity 
Synthetic compounds that behave like estrogen in some tissues such as bone, 
while in others such as breast and uterus they block the estrogen activity are 
of great clinical relevance. The most well known SERMs are tamoxifen and 
raloxifene (144). Tamoxifen is an ER antagonist in the breast and it is 
available as endocrine therapy for postmenopausal women with ER-positive 
breast cancer. Raloxifene is mainly approved for treatment and prevention of 
osteoporosis. Like tamoxifen, raloxifene acts as an estrogen antagonist in 
breast tissue. Both tamoxifen and raloxifene are agonists in the uterus and 
liver. This results in increased incidences of uterine cancer and 
thromboembolic phenomena. The relative risk of venous thrombosis is 
increased two to three-fold with each of these medications (144, 145). 
Because of these side-effects, the development and improvement of new 
selective estrogen receptor modulators is an ongoing process. 
Recently, it was proposed by Kousteni et al. (105) that the synthetic 
compound estren has non-genomic bone-sparing effects via stimulation of 
the Src/shc/extracellular-signal regulated kinase (ERK) and repression of the 
c-Jun N-terminal kinase (JNK) signaling cascades, leading to downstream 
modulation of the activity of transcription factors such as Elk-1, 
CCAAT/enhancer binding protein ß (C/EBPß), CREB, and c-Fos/c-Jun (70). 
These bone-sparing effects are clearly distinguished from the effects on the 
uterus, which is via the classic genomic pathway, with no effects of estren on 
the reproductive tissues. Therefore, estren has been suggested to be a 
mechanism-specific ligand of t he ERs or the AR rather than being a t issue-
specific ligand such as SERMs/SARMs. This finding, if accurate, is extremely 
important since one of the most crucial tasks in the development of new 
therapeutic agents for treatment of osteoporosis is to distinguish the bone-
sparing effects from the effects on the reproductive tract. In our study, using 
a slightly lower dose of estren than that used by Kousteni et al., estren 
increased not only the trabecular BMD but also the uterine weight after ovx 
in female mice. The discrepancy between the findings in the two studies is 
difficult to explain, but it might be attributable to the differences in 
administration route. In the previous study, 60-day slow-release pellets were 
used. It might be possible that the delivery of estren was reduced during the 
last few days of the treatment period and therefore the effect on the uterus, 
which is a fast-responding tissue, was lost, while it remained in the more 
slow-responding bone tissue. In our study, daily injections were used for 
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administration, which ensured an unvarying dose over the whole treatment 
period. 
The previously proposed lack of transcriptional activity for estren was 
explained after in vitro studies in ERa-transfected HeLa cells (70). However, 
the estrogenic effect in HeLa cells is exclusively dependent on AF-2, since 
these cells lack AF-1 (146, 147). In the 293 kidney epithelial ERa- and ERß-
expressing cells (148) used by us, estren had as good agonistic effect on the 
ERE-dependent transcriptional activity as 17ß-estradiol, both in the presence 
of ERa and in the presence of ERß. This demonstrates that the cell line 
selected for the experiment and its specific cellular environment is of great 
importance for the activity of estren. It was further confirmed that estren 
actually has classic transcriptional activity by use of the ER antagonist ICI 
182,780 which, in a dose-dependent manner, antagonised the effects of 
estren on the transcription machinery. Although these results do not exclude 
non-genomic effects of estren, they clearly demonstrate, in contrast to 
previous findings, that estren has transcriptional activity. 
Estren has also been proposed to act via both the ERs and the AR (70, 
105). Cross-reactivity between the ERs and AR for mediation of the bone-
sparing effects has also been proposed for the natural ligands for the 
receptors (70). However, as early as in papers I and II, we showed that the 
bone-sparing effect on the trabecular bone of 17ß-estradiol and DHT is 
dependent on ERa and AR, respectively, while no cross-reactivity between 
the two receptors was found. In the present study, we show that ERs were 
required for the action of estren on the trabecular bone since no effect was 
found after estren treatment in the ovx double ER-inactivated mice. 
However, we have shown that estren inhibits T lymphopoiesis via ER-
independent pathways, whereas its suppression of peripheral immune 
functions is ER-dependent (149). We have also demonstrated that estren is 
able to signal through the AR since estren has similar effects as DHT on 
lymphopoiesis in thymus and bone marrow, and on submandibular glands 
(150). These effects are all independent of the estrogen receptors since they 
were all present in double ER-inactivated female mice. It has also been 
demonstrated in male mice that estren has transcriptional activity via the AR 
(151). Taken together, these data show that estren has the capacity to activate 
the classic genomic transcriptional machinery via ERa, ERß, and AR, 
although its activity is regulated differently in different tissues. Since it is 
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clear that estren is not bone-specific but also affects the reproductive organs, 
it is no longer a promising candidate for treatment of osteoporosis. 
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Conclusions 
In this thesis, we demonstrate that both ERa and AR activation in adult male 
mice prevent orx-induced trabecular BMD loss, whereas ERß is of no 
importance. ERa and AR activation increase the trabecular BMD by two 
distinct mechanisms since ERa activation increases both the thickness and 
number of the trabeculae while AR activation increases the number of the 
trabeculae but not the thickness. Furthermore, the bone parameters affected 
only by ERa correlate with serum levels of IGF-I, indicating that the effects 
mediated exclusively by ERa are mediated via IGF-I. We also show in 
ovariectomized female rats that a combination of ERa and AR activation has 
an additive effect on the trabecular BMD. In addition, we demonstrate for 
the first time in vivo that ERß can function as a repressor of ERa mediated 
gene transcription. The notion that ERß exhibits an inhibitory effect on 
ERa-mediated gene expression and in many instances opposes the actions of 
ERa must be taken into account when developing SERMs with an ERß 
antagonist effect. The role of ERß antagonists might be to enhance the effects 
of ERa activation more than to have direct effects on the transcriptional 
machinery. In conclusion, since the bone-sparing effects of ERa and AR 
activation in adult male mice are clearly distinct from each other, a 
combination of SERM and SARM might be beneficial in the treatment of 
osteoporosis. 
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Two Different Pathways for the Maintenance of Trabecular 
Bone in Adult Male Mice 
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ABSTRACT 
Androgens may regulate the male skeleton either directly via activation of the androgen receptor (AR) or 
indirectly via aromatization of androgens into estrogen and, thereafter, via activation of estrogen receptors 
(ERs). There are two known estrogen receptors, ER-a and ER-ß. The aim of this study was to investigate the 
relative roles of ER-a, ER-ß, and AR in the maintenance of trabecular bone in male mice. Seven-month-old 
male mice, lacking ER-a (ERKO), ER-ß (BERKO), or both receptors (DERKO), were orchidectomized (orx) 
and treated for 3 weeks with 0.7 fig/mouse per day of 17ß-estradiol or vehicle. No reduction in trabecular bone 
mineral density (BMD) was seen in ERKO, BERKO, or DERKO mice before orx, showing that neither ER-a 
nor ER-ß is required for the maintenance of a normal trabecular BMD in male mice. After orx, there was a 
pronounced decrease in trabecular BMD, similar for all groups, resulting in equal levels of trabecular BMD 
in all genotypes. This reduction was reversed completely in wild-type (WT) and BERKO mice treated with 
estrogen, and no significant effect of estrogen was found in ERKO or DERKO mice. In summary, the 
trabecular bone is preserved both by a testicular factor, presumably testosterone acting via AR and by an 
estrogen-induced activation of ER-a. These results indicate that AR and ER-a are redundant in the 
maintenance of the trabecular bone in male mice. In contrast, ER-ß is of no importance for the regulation of 
trabecular bone in male mice. (J Bone Miner Res 2002;17:555-562) 
Key words: estrogen receptors, androgens, bone, transgenic, males 
INTRODUCTION 
MORBIDITY FROM osteop orosis in the aging population is substantial in both men and women. However, few 
studies have been designed for the elucidation of the mech-
anism(s) behind male osteoporosis. It is obvious that andro­
gens are important both for the acquisition o f bone during 
skeletal growth and for the maintenance of t rabecular bone 
The authors have no conflict of interest. 
in adults. The effects of testosterone on the skeleton can be 
exerted either directly via the androgen receptor (AR) or 
indirectly via aromatization to estrogen and further via 
estrogen receptors (ERs). Orchidectomy (orx) results in 
bone loss, which is prevented by treatment with andro-
gens.(1,2) However, estrogen treatment also prevents orx-
induced bone loss.(l,2) Humans, as well as rodents, with 
impaired aromatase activity, suffer from decreased bone 
mineral density (BMD),(,-8) which can be prevented by 
treatment with estrogen/3,5,9,l0) Furthermore, several stud-
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^Department of Medicine, Loma Linda University, Musculoskeletal Disease Center, Pettis Veterans Administration Medical Center. 
Loma Linda, California, USA. 
4Department of Medical Nutrition, Karolinska Institute, Novum, Huddinge, Sweden. 
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ies have presented stronger correlations between BMD and 
estrogen than with testosterone.'1,-13) These experimental 
and clinical data support the importance of estrogen in the 
maintenance of normal BMD in males. There are two 
known ERs, denoted a (ER-a) and ß (ER-/3). Previously, 
we have shown that ER-a, but not ER-ß, mediates impor­
tant effects of estrogen in the regulation of skeletal growth 
in male mice.(l4) However, the relative importance of ER-a 
and ER-ß in the regulation of adult bone metabolism in 
male mice is unknown. The lack of ER-a in male mice 
results in elevated serum levels of estrogen and testosterone, 
probably because of disturbed feedback regulations.(,5) 
Therefore, to avoid confounding effects of elevated sex ste­
roids, the ER-inactivated and wild-type (WT) mice used in this 
study were orx. The mice were substituted with 17/3-
estradiol or vehicle and the ER specificity in th e regulation 
of the adult bone metabolism in males was investigated. 
MATERIALS AND METHODS 
Animals 
Male double heterozygous (ER-a:+/~ß+/_) mice were 
mated with female double heterozygous (ER-a+/-ß+/~) 
mice, resulting in WT, ER-a_/~ER-ß + /+ (ERKO), 
ER-a+/+ER-ß_/~ (BERKO) and ER-a-/~ER-ß~ /_ 
(DERKO) offspring with a mixed C57BL/6J/129 back­
ground.'I6,7> Genotyping of tail DNA was performed at 3 
weeks of age as previously described/141 Animals had free 
access to fresh water and food pellets (B & K Universal AB, 
Sollentuna, Sweden) consisting of cereal products (76.9% 
barley, wheat feed, wheat, and maize germ), vegetable 
proteins (14.0% hipro soya), and vegetable oil (0.8% soya 
oil). All mice were orx at the age of 7 months. The mice 
were left to recover for 10 days after orx. After r ecovery, 
mice were injected subcutaneously (sc) with 0.7 /xg/mouse 
per day of 17ß-estradiol benzoate (Sigma, St. Louis, MO. 
USA) for 5 days/week during 3 weeks. Control mice re­
ceived injections of vehicle oil (olive oil; Apoteksbolaget, 
Göteborg. Sweden). Treatment with 0.7 /xg/mouse per day 
of 17ß-estradiol benzoate resulted in 17ß-estradiol levels of 
~220 pmol/liter, which could be regarded as physiologi­
cally relevant concentrations of 17ß-estradiol. 
Dual X-ray absorptiometry 
Measurement o f bone mineral content (BMC) and areal 
BMD (aBMD) of total body i n vivo and femur in vitro was 
performed with the Norland Medical Systems pDEXA Sa­
bre (Norland Medical Systems. Fort Atkinson, WI. USA) 
and the Sabre Research software (v3.6; Norland Medical 
Systems, Fort Atkinson. Wl, USA) as previously de­
scribed.'l4- ,8) 
Peripheral quantitative computerized tomography 
Computerized tomography (CT) was performed with the 
Stratec pQCT XCT Research M (v5.4B: Norland Medical 
Systems) operating at a resolution of 70 /xm a s previously 
described.'18) Cortical parameters were determined with a 
middiaphyseal peripheral quantitative CT (pQCT) scan of 
the tibias. Trabecular BMD was determined with a metaph­
yseal pQCT scan of the proximal tibias and defined as the 
inner 45% of the total area. 
H istomorphometry 
The left tibia was fixed in 10% phosphate-buffered for­
malin, embedded in methacrylate resin, sectioned, and 
stained by Goldner's trichrome method. Analysis of trabec­
ular bone was restricted to an area 0.25-2 mm in a diaph­
yseal direction from the growth plate, maintaining separa­
tion between the analysis area and the cortical wall. 
Histomorphometric parameters measured were trabecular 
bone volume (BV/TV; %), trabecular thickness (Tb.Th: 
/xm), trabecular separation (Tb.Sp; /xm), and trabecular 
number (Tb.N: mm-1)."91 
Mechanical testing 
After pQCT measurements, the humerus was applied to 
mechanical testing using Mechanical Tester 8841 (Instron, 
Canton. MA, USA). Three-point bending force was mea­
sured by placing the bone horizontally with the anterior 
surface upward and applying pressing force vertically to the 
midshaft of the bone. Each bone was compressed with a 
constant speed of 2 mm/minute until failure. Breaking force 
(maximal load) was defined as bending load at failure. 
Maximal stress (sigma) and elastic or Young's modulus (E) 
were calculated as previously described.'201 
Radioimmunoassay 
Serum insulin-like growth factor (IGF) I levels were 
measured by double antibody IGF binding protein-blocked 
radioimmunoassay (RIA).C2I) Serum osteocalcin levels were 
measured using a monoclonal antibody raised against hu­
man osteocalcin (Rat-MID osteocalcin ELISA: Osteometer 
Biotech A/S. Herlev, Denmark). The sensitivity of the os­
teocalcin assay was 21.1 ng/ml and intra- and interassay 
coefficients of variation (CVs) were <10%. Levels of 
c-telopeptide were measured in serum by ELISA, which 
measures degradation products of type I collagen, generated 
by osteoclastic bone resorption.'221 The sensitivity of the 
ELISA was <0.1 ng/ml. The average intra- and interassay 
CVs were <12%. I7ß-estradiol was measured using an RIA 
detecting estradiol (DiaSorin, Saluggia, Italy) with sensitiv­
ity below 5 pg/ml at 95% confidence limit. 
Tartrate-resistant acid phosphatase 5b activity 
Tartrate-resistant acid phosphatase (TRAP) 5b, purified 
from human osteoclasts as described/231 was used as anti­
gen to develop a polyclonal antiserum in rabbits.'241 The 
antiserum was incubated on anti-rabbit immunoglobulin G 
(IgG)-coated microtiter plates (EG & G Wallac, Turku. 
Finland) for 1 h. Diluted mouse serum samples were incu­
bated in the wells for 1 h, and bound enzyme activity was 
detected using 8 mmol/liter of 4-nitrophenylphosphate (4-
NPP) as substrate in 0.1 M of sodium acetate buffer. pH 6.1, 
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FIG. 1. Total body aBMD measured using DXA. Seven-month-old 
male mice were orx and treated with vehicle (V) or 17/3-estradiol (E ) 
for 3 weeks (intact animals |n = 14), orx animals [n = 4-61). Values 
aie given as means ± SEM: '  A  p < 0.01 versus intact  mice and **p < 
0.01 versus vehicle. Student's /-test. 
for 2 h at 3 7°C. The enzyme reactions were terminated by 
adding 25 fxl of 0.32 M of NaOH, and A405 was measured 
using Victor2 eq uipment (EG & G Wallac). 
RESULTS 
aBMD and BMC as determined by dual-energy X-ray 
absorptiometry 
In vivo a nalysis of the total bod y aBMD in 7-month-old 
intact male mice revealed a slight decrease in ERKO 
(—2.7%) and DERKO (-3.6%) but not in BERKO com­
pared with WT mice (p < 0.05; one-way analysis of vari­
ance [ANOVA], followed by Student-Newman-Keurs mul­
tiple range test; Fig. 1). After orx, the total body aBMD 
decreased to a similar ex tent in all four genotypes. Treat­
ment with 17/3-estradiol incre ased total b ody aBMD in WT 
and BERKO as compared with ve hicle t reatment, whereas 
no estrogenic effect was found in E RKO or DERKO mice 
(Fig. 1). After death the left femur was excised and analyzed 
by dual-energy X-ray absorptiometry (DXA) in vitro. Treat­
ment with 17ß-estradiol increased the femoral aBMD in 
WT and BERKO, whereas no effect was seen in E RKO or 
DERKO mice (Fig. 2A). The estrogen-induced increase in 
aBMD in WT and BERKO mice resulted in a similar 
increase in femur BMC (Fig. 2B). Thus, the effect of 
17ß-estradiol on femoral BMC in orx mice is ER-a-
mediated. In contrast, no effect of treatment with 17/3-
estradiol was seen on the femur area (Fig. 2C). 
The results obtained from DXA measurements are a 
combination of effects on trabecular bone and cortical bone 
parameters. To be able to distinguish between effects of 
17ß-estradiol on trabecular and cortical bone, the mice were 
analyzed by p QCT. 
Trabecular BMD as determined by pQCT 
The trabecular volumetric BMD (tvBMD) was measured 
in the metaphyseal region of the proximal tibias using 
pQCT. Measurements of tvBMD before orx revealed a 
slight increase in ERKO and DERKO (p < 0.01; one-way 
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FIG. 2. Femur (A) aBMD (B) BMC. and (C) area measured using 
DXA. Seven-month-old male mice were orx and treated with vehicle 
(V) or 17/3-estradiol (E) for 3 weeks (n = 4-6). Values are given as 
means ± SEM; *p < 0.05 and **p < 0.01 versus vehicle. Student's 
f-test. 
ANOVA, followed by Student-Newman-Keul's multiple 
range test), whereas no difference was seen in BERKO 
compared with W T mice (Figs. 3A and 3B). After orx, the 
tvBMD decreased dramatically to the same level in all 
genotypes. Treatment with 17ß-estradiol prevented this de­
crease in WT and BERKO mice, whereas no effect of 
17/3-estradiol was seen in ERKO or DERKO mice (Figs. 3A 
and 3 B). 
Histomorphometry 
Histomorphometry of the metaphyseal part of the proxi­
mal tibias was performed to confirm the effects on trabec-
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FIG. 3. (A) tvBMD of tibias measured using 
pQCT. (B) Representative pQCT scans. Seven-
month-old intact (I) male mice were orx and 
treated with either vehicle (V) or 17/3-estradiol 
(E) for 3 weeks. Intact animals (n = 14) and orx 
animals (n = 4-6). Values are given as 
means ± SEM. f 1 p < 0.01 versus intact mice, 
*/> < 0.05. and **p < 0.01 versus vehicle. 
Student's r-test. H. high bone mineral density; L, 
low bone mineral density. 
ular bone as detected by pQCT. Trabecular bone volume as 
a ratio to total bone volume (BV/TV) was well correlated to 
tvBMD as measured using pQCT (R = 0.76; p — 3.1 X 
10-8). Estrogen treatment increased the BV/TV in WT. 
Statistical analysis in which ER-aw+ (WT and BERKO) 
and ER-ai_/- (ERKO and DERKO) mice were analyzed 
independently indicated that 17ß-estradiol treatment in­
creased BV/TV in ER-a+/+ animals but not in ER-aT/_ 
animals (p < 0.01; two-way ANOVA, followed by Student-
Newman-Keul's multiple range test; Table 1), confirming 
our results of the effect of 17/3-estradiol o n tvBMD as 
measured using pQCT. Tb.Sp was decreased and Tb.N was 
increased after estrogen treatment in WT and BERKO mice, 
whereas no effect was seen in ERKO or DERKO mice 
(Table 1). 
Cortical bone parameters (pQCT) 
Cortical bone parameters (BMC, area, and thickness) 
were measured by a middiaphyseal pQCT scan of the tibias. 
These cortical bone parameters were decreased in 7-month-
old intact ERKO and DERKO but not in BERKO mice 
compared with WT mice (data not sh own). Cortical BMC 
was increased after estrogen treatment in WT and BERKO 
but not in ERKO or DERKO mice (Table 2). Similar 
tendencies were seen regarding both cortical thickness and 
cross-sectional area (Table 2). Statistical analysis in wh ich 
ER-«+/+  (WT and BERKO) and ER-aT'~ (ERKO and 
DERKO) mice were analyzed independently showed that 
17/3-estradiol treatment increased all these cortical bone 
parameters in orx ER-a+/+ (BMC, 24 ± 4% and p < 0.01; 
thickness, 16 ± 3% and p < 0.01; cross-sectional area, 
19 ± 3% over vehicle and p < 0.01; two-way ANOVA. 
followed by S tudent-Newman-Keul's multiple range test), 
whereas no effect was seen in E R-aT/_ mice. 
Mechanical strength 
The mechanical strength was measured using three-point 
bending of the h umerus. Maximal load, a measurement of 
the strength of the bone, was increased a fter 17/3-estradiol 
treatment in or x ER-a+/+ (WT and BERKO) m ice (28 ± 
8% over vehicle and p < 0.01 two-way ANOVA, followed 
by Student-Newman-Keul's multiple range test). No effect 
of 17ß-estradiol treatment was seen in ER-a~/_ (ERKO 
and DERKO) mice, showing an ER-a-mediated effect. The 
qualitative bone parameter maximal stress and elastic mod-
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WT ERKO BERKO DERKO 
BV/TV (%) V 3.0 ± 0.8 4.7 ± 0.5 5.6 ± 0.8 5.2 ± 1.1 
E 11.7 ± 3.3* 6.0 ± 1.3 11.9 ±2.8* 6.0 ± 1.2 
Tb.Sp (/xm) V 983 ± 206 545 ± 55 613 ±71 684 ± 106 
E 419 ± 106* 565 ± 119 347 ± 83* 481 ± 50 
Tb.N (mm-1) V 1.1 ± 0.2 1.8 ± 1.2 1.6 ± 0.9 1.5 ±0.3 
E 2.6 ± 0.7* 1.9 ±0.4 3.2 ± 0.6* 2.0 ± 0.2 
Tb.Th (/xm) V 26.8 ± 3.5 25.9 ± 2.9 34.0 ± 4.2 36.5 ± 10.8 
E 44.0 ± 2.7+ 31.1 ± 1.7 36.5 ± 5.7 28.9 ± 2.6 
Histomorphometric analysis was performed on proximal tibia from orx mice treated with vehicle (V) or 17/3-estradiol (E) for 3 weeks. 
BV/TV, Tb.Sp, Tb.N, and Tb.Th were measured. Values are given as means ± SEM (n = 4-6). 
*p < 0.05; fp < 0.01; *p = 0.056 versus vehicle. Student's /-test. 
TABLE 2. CORTICAL BONE PA RAMETERS 
WT ERKO BERKO DERKO 
BMC (mg/mm) V 0.89 ±0.04 0.81 ±0.06 0.87 ± 0.02 0.85 ±0.03 
E 1.08 ± 0.07* 0.88 ±0.05 1.09 ± 0.04+ 0.80 ±0.03 
Thickness (/xm) V 185 ± 10 179 ± 8 183 ±4 191 ± 5 
E 214 ± 12 201 ±8 214 ± 5f 183 ±7 
Cross-sectional area (mm2) V 0.79 ±0.02 0.73 ± 0.05 0.80 ± 0.02 0.77 ±0.02 
E 0.94 ±0.06* 0.79 ±0.05 0.94 ± 0.03+ 0.72 ±0.03 
Cortical bone pa rameters were determined using a middiaphy seal p QCT scan of the tibia fro m orx mice treated with vehicle (V ) or 
17/3-estradiol (E). Value s are given as means ± SEM (n = 4-6). 
*p < 0.05; +/> < 0.01; *p = 0.053 versus vehicle. Student's/-test. 
TABLE 3. SERUM PA RAMETERS 
WT ERKO BERKO DERKO 
Osteocalcin (ng/ml) V 88.0 ± 4.9 162.6 ± 47.1 133.3 ±7.2 130.3 ± 22.5 
E 114.9 ± 36.3 150.7 ± 22.1 111.4 ± 14.7 142.5 ± 10.6 
c-Telopeptide (ng/ml) V 14.7 ± 1.4 10.9 ± 0.9 10.8 ± 0.3 8.7 ± 1.0 
E 10.6 ± 0.8* 8.8 ± 1.1 10.4 ± 1.4 11.2 ±0.9 
TRAP 5b (U/liter) V 3.0 ± 0.2 3.0 ± 0.2 3.1 ±0.2 2.8 ± 0.4 
E 5.3 ± 0.7* 3.1 ± 0.4 5.2 ± 0.8+ 3.2 ± 0.2 
IGF-I (ng/ml) V 210.6 ± 27.7 222.6 ±21.6 284.8 ± 25.9 270.5 ± 32.6 
E 319.7 ± 44.7 248.4 ± 21.1 286.9 ± 17.4 265.3 ± 28.3 
Serum was collected from orx mice treated with vehicle (V) or 17ß-estradiol (E) for 3 weeks. Values are given as means ± SEM (n = 4-6). 
*p < 0.05; +p < 0.01 versus vehicle. S tudent's /-test. 
ulus were not affected by 17ß-estradiol treatment in any 
genotype (data not shown). 
Serum levels of biochemical hone parameters and 
IGF-/ 
Serum parameters were measured at death after 3 weeks 
of treatment with estrogen or vehicle to orx mice. No major 
effects of 17/3-estradiol treatment were seen on the serum 
levels of osteocalcin or c-telopeptide (Table 3). The activity 
of TRAP 5b, an osteoclast-specific enzyme, was increased 
after 17/3-estradiol treatment in WT and BERKO mice, 
whereas no effect was detected in ERKO or DERKO mice 
as compared with vehicle treatment (Table 3). The activity 
of TRAP 5b was correlated to tvBMD. as determined using 
pQCT (R = 0.76; p = 4.4 X 10"8) as well as BV/TV. 
determined by histomorphometry (R = 0.75; p — 1.1 X 
10-7). Serum levels of IGF-I were not significantly affected 
by estrogen treatment in any of the genotypes (Table 3). 
DISCUSSION 
Estrogen is of importance for the regulation of skeletal 
growth and maturation in female mice and an increasing 
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Effects of Androgens on 
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FIG. 4. Effects of androgens on trabecular bone in male mice. (A) 
Three different possible pathways for androgens in the regulation of 
trabecular bone in male mice aie indicated. (B) Our present data 
together with some previous findings show that the trabecular bone i s 
preserved both by an activation of ERa and by an activation of the 
AR."-25» Thus, we propose that the AR and ER-a are redundant in t he 
regulation of trabecular bone in male mice. I n contrast, ER-ß is of no 
importance for the regulation of trabecular bone in male mice. 
amount of data indicates that estrogen is of importance in 
male mice as well. Previously, we have shown that the 
skeletal growth of the long bones in male mice is dependent 
on estrogen, because combined loss of both ER-a and ER-ß 
results in impaired longitudinal bone growth. This pheno-
type also was seen in ma le ERKO. but not in male BERKO 
mice, showing an ER-a-mediated effect/,4) Male aro-
matase deficient mice (ArKO) have shorter femurs than 
their normal littermates (NLMs), further supporting the 
importance of estrogen in the regulation of longitudinal 
bone growth in male mice.(6) Interestingly, androgens acting 
directly on the AK were not able to substitute for the loss of 
ER-a in the stimulation of longitudinal bone growth in male 
mice.(l4) Thus, ER-a and AR are not redundant regarding 
the regulation of longitudinal bone growth in m ale mice. 
Our previous study, analyzing ER-inactivated young 
adult male mice with intact gonads, did not detect any major 
effect on the amount of trabecular bone. However, these 
ER-inactivated mice have increased levels of endogenous 
estrogen and testosterone, which might have confounded 
the results on the amount of trabecular bone.(,5'25) There­
fore, to avoid confounding effects of e levated sex steroids, 
the ER-inactivated and WT mice used in this study were 
orx. Androgens may regulate the amount of trabecular bone 
either directly via activation of AR or indirectly via aroma­
tization into estrogens and further via activation of ERs 
(Fig. 4A). A protective role of estrogen on trabecular bone 
is supported by the fact that aromatase deficiency in male 
mice(69) as well as aromatase inhibition in male rats(7'8) 
results in a slight decrease in the amount of trabecular bone. 
Treatment with estrogen prevents this bone loss.(9IO) This 
study confirms some previous studies by showing that orx-
induced trabecular bone loss is prevented by estrogen treat-
ment.(, 2) However, for the first time, we have elucidated the 
ER specificity for this bone-sparing effect of estrogen in 
male mice. 17/3-Estradiol treatment of orx male mice pre­
vents trabecular bone loss in WT and BERKO but not in 
ERKO or DERKO mice. This finding clearly shows that the 
protective effect of estrogen on trabecular bone in adult 
male mice is mediated via ER-a. and ER-ß is of no impor­
tance. 
The orx of adult male rats causes trabecular bone loss that 
can be prevented both by testosterone and by nonaromatiz-
able androgen dihydrotestosterone (DHT).n> These data 
show a protective role of androgens on the trabecular bone 
via activation of AR (Fig. 4B). In thi s study, the physiolog­
ical role of AR in the regulation of trabecular bone was 
analyzed indirectly. The fact that the trabecular BMD is 
preserved in E R-a as well as in ER-a/ß double-inactivated 
male mice with intact gonads indicates that a testicular 
factor, presumably testosterone acting via the AR, is able to 
maintain a normal trabecular BMD. This notion is sup­
ported by a recent study in which testosterone prevented 
orx-induced bone loss in ERKO mice.(25) F urthermore, the 
orx-induced trabecular bone loss in this study is similar in 
WT and DERKO mice. Thus, a testicular factor is a ble to 
maintain the trabecular bone in male mice devoid of all 
known ERs. Because a similar magnitude of orx-induced 
trabecular bone loss is seen in m ice having functional ERs 
and in m ice devoid of a ll known ERs, this testicular factor 
is most likely acting via the AR. Previous studies indicate 
that the serum levels of t estosterone in orx rats are 5-10% 
of that in intact rats.<7) Therefore, one cannot exclude that a 
low background concentration of adrenal-derived androgens 
may have reduced the effect of removal of t esticular andro­
gens. Our present data together with previous findings11,25* 
show that trabecular bone is preserved both by an activation 
of ER-a and by an activation of the AR (Fig. 4B). Neither 
male mice with ER-a inactivation n or rats with a n onfunc­
tional AR suffer from any major trabecular bone loss.<26) 
Thus, we propose that t he AR and ER-a are "redundant" in 
the regulation of trabecular bone in m ale rodents (Fig. 4B). 
In contrast, as discussed previously, no redundancy between 
ER-a and AR was seen for the regulation of longitudinal 
bone growth in m ale mice. 
A recent in vitro study indicated that both androgens and 
estrogens are able to exert nongenomic effects via activation 
of either the AR or ERs.<27) W e could not detect any effect 
of estrogen on the trabecular bone in orx male DERKO 
mice, suggesting that an in vivo effect o f estrogen via the 
AR is unlikely. However, our study does not rule out the 
possibility that androgens might be able to exert effects via 
ERs. Treatment of orx AR-deficient mice with nonaroma-
tizable DHT could test this possibility. 
Young adult ERKO and DERKO but not BERKO mice 
with intact gonads have decreased cortical BMC compared 
with WT mice, s howing that the estrogenic regulation of 
cortical BMC is mediated via ER-a.(14) Treatment of adult 
orx mice with estrogen resulted, in this study, in a small but 
significant increase in the cortical BMC in WT and BERKO 
male, whereas no effect of estrogen treatment was found in 
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ERKO or DERKO mice. In addition, these data show that 
the effects of estrogen on adult cortical BMC are mediated 
via ER-a and not ER-/3. The effects on cortical BMC were 
reflected by similar changes in mechanical strength as mea­
sured by three-point bending. Estrogen increased the max­
imal l oad in ER-a+/+ but not in ER-a-/~ mice. However, 
there was no effect on qualitative bone parameters, includ­
ing elastic modulus and maximal stress, indicating that the 
quality of the cortical bone is not affected by estrogen 
treatment. 
Analysis of to tal body areal BMD using DXA revealed a 
small decrease in intact ERKO and DERKO mice compared 
with WT mice. T he image produced by the DXA is two-
dimensional and does not recognize changes in the third 
dimension. Therefore, the reduction in areal BMD seen in 
male ERKO and DERKO mice with intact gonads probably 
is caused by decreased size of the animals and does not 
reflect a true decrease in vBMD. 
Serum levels of osteocalcin, a marker of bone formation, 
and c-telopeptide, a marker of bone resorption, were mea­
sured at the end of the study after 3 weeks of treatment with 
estrogen. No major effect of estrogen was detected for these 
markers in any genotype. On the contrary, the recently 
described new bone resorption marker, serum TRAP 5b 
activity/28'29* was increased after estrogen treatment in WT 
and BERKO mice whereas the activity was unaffected by 
estrogen treatment in ERKO and DERKO mice. It i s well 
known that the acute effect of estrogen in gonadectomized 
rodents is to decrease TRAP 5b.(30) In contrast, in this study 
we have found that TRAP 5b activity is increased after a 
prolonged estrogen treatment. Interestingly, the increased 
TRAP 5b levels were correlated with the amount of trabec­
ular bone. S imilarly, recently, we reported that long-term 
orx results in a decreased TRAP 5b activity, associated with 
a decrease in trabecular BMD.<30) Thus, one might speculate 
that TRAP5b reflects the amount of trabecular bone after a 
prolonged estrogen treatment. In summary, the trabecular 
bone is preserved both by a testicular factor, presumably 
testosterone acting via AR, and by an estrogen-induced 
activation of ER-a. These results indicate that AR and ER-a 
are redundant in the maintenance of the trabecular bone in 
male mice (Fig. 4B). In contrast, ER-/3 is of n o importance 
for the regulation of trabecular bone in male mice. 
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Androgens may regulate the male skeleton either directly by 
stimulation of the androgen receptor (AR) or indirectly by aroma-
tization of androgens into estrogens and, thereafter, by stimula­
tion of the estrogen receptors (ERs). To directly compare the effect 
of ER activation on bone in vivo with the effect of AR activation, 
9-month-old orchidectomized wild-type and ER-inactivated mice 
were treated with the nonaromatizable androgen 5a-dihydrotes-
tosterone, 17/3-estradiol, or vehicle. Both ERa and AR but not ER/3 
activation preserved the amount of trabecular bone. ERa activation 
resulted both in a preserved thickness and number of trabeculae. 
In contrast, AR activation exclusively preserved the number of 
trabeculae, whereas the thickness of the trabeculae was un­
affected. Furthermore, the effects of 17/3-estradiol could not be 
mediated by the AR, and the effects of 5a-dihydrotestosterone 
were increased rather than decreased in ER-inactivated mice. ERa, 
but not AR or ER/3, a ctivation resulted in preserved thickness, 
volumetric density, and mechanical strength of the cortical bone. 
ERa activation increased serum levels of insulin-like growth factor 
I, which were positively correlated with all the cortical and trabec­
ular bone parameters that were specifically preserved by ERa 
activation but not by AR activation, suggesting that insulin-like 
growth factor I might mediate these effects of ERa a ctivation. 
Thus, the in vivo bone-sparing effect of ERa activation is distinct 
from the bone-sparing effect of AR activation in adult male mice. 
Because these two pathways are clearly distinct from each other, 
one may speculate that a combined treatment of selective ER 
modulators and selective AR modulators might be beneficial in the 
treatment of osteoporosis. 
Sex steroids are important not only for the maintenance of the female skeleton, but also for the male skeleton. The relative 
contribution of a ndrogens versus estrogens in th e regulation of 
the male skeleton is unclear. Testosterone replacement therapy 
increases bone mineral density (BMD) in hypogonadal men (1), 
but several clinical studies indicate that BMD is correlated more 
to serum levels of estradiol than to serum levels of testosterone 
in males (2-4). A previous clinical study, which directly com­
pared estrogen versus testosterone effects on bone, showed that 
estrogens play the dominant role in the regulation of bone 
resorption markers, whereas both estrogens and testosterone 
contribute to the maintenance of markers for bone forma­
tion (5). 
The effects of testosterone can be exerted e ither directly by 
means of the androgen receptor (AR) or indirectly by aroma-
tization to estrogens and further by es trogen receptor (ER)a 
and/or ER/3. All three sex steroid receptors are expressed both 
in growth-plate cartilage and in bone (6-11). Functional studies 
using sex steroid receptor-inactivated animal models have dem­
onstrated that ERa but not ER/3 is important for the regulation 
of ap pendicular longitudinal skeletal growth in m ale mice (12-
www.pnas.org/cgi/doi/10.1073/pnas.2233084100 
14), and a recent report indicates that AR-inactivated male mice 
have unaffected bone length (15). 
Orchidectomy (orx) decreases the amount of trabecular and 
cortical bone in adult rodents. We and others have shown that 
the trabecular bone-sparing effect of estrogens is present in orx 
ERß~'~ but not in ERa~/_ or ERa_/~~/3~/_ mice, demonstrating 
that ERa but not ER/3 mediates the trabecular bone-sparing 
effect of estrogens in male mice (16-18). Interestingly, orx 
resulted in de creased trabecular volumetric BMD (tvBMD) in 
ERa-/~/3-/_ mice, indirectly demonstrating that a testicular 
factor, probably acting by means of the AR, is also of importance 
for the maintenance of t vBMD in male mice (16). 
It was recently demonstrated in vitro that the ERs and the AR 
transmit the antiapoptotic signal in osteoblasts with the same 
efficiency irrespective of whether the ligand is an estrogen or an 
androgen (19). To directly compare in vivo in males the effect of 
ER activation on bone with the effect of AR activation, orx WT 
and ER-inactivated mice were treated with the nonaromatizable 
androgen 5 a-di hydro testosterone (DHT), 17/3-estradiol, or ve­
hicle. We here demonstrate that the in vivo effect of ER 
activation on bone is clearly distinct from the effect of AR 
activation in adult male mice. 
Materials and Methods 
Animals. Male and female double heterozygous (ERa+/~/3+/~) 
mice were mated, resulting in WT, ERa_/_ER/3+/+ (ERa-/~), 
ERa+/+ERß_/" (ER/3- /~), and ERa~'~ERß~'~ (ERa''-ß~'~) 
offspring as described (12). Animals had free access to fresh 
water and food pellets (B&K Universal AB, Sollentuna, Swe­
den), consisting of cereal products (76.9% barley, wheat feed, 
wheat feed, and maize germ), vegetable proteins (14.0% hipro 
soya), and vegetable oil (0.8% soya oil). At 9 months of age, mice 
were orchidectomized or sham-operated and treated for 4 weeks 
with 17/3-estradiol (0.05 /xg/day) or DHT (45 /Ag/day), admin­
istered by m eans of s .c. silastic implants (Silclear Tubing, De-
gania Silicone, Jordan Valley, Israel) in the cervical region (20). 
Vehicle animals received empty implants. 17/3-Estradiol and 
DHT were obtained from Sigma. The Ethics Committee of 
Göteborg University approved this study. 
Peripheral Quantitative Computerized Tomography (pQCT). CT was 
performed with the PQCT XCT RES EARCH M (Version 4.5B, 
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Table 1. Weight of seminal vesicles and ventral prostate 
Parameter Sham orx + V orx + E orx + DHT 
Seminal vesicle weight, mg 
WT 347.4 ± 26.8 32.6 ± 6.2ft 42.7 ± 13.6+t 379.2 ± 25.1** 
ERcr/-ß-/- 453.8 ± 33.4 134.7 ± 21.2+ 211.3 67.6+ 615.0 ± 71.8** 
Ventral prostate weight, mg 
WT 20.0 ± 2.5 4.0 ± 0.7tf 6.2 ± 2.0ft 16.6 ± 1.8** 
ERa-/-/3-/- 18.7 ± 2.2 6.4 ± 0.3f 6.5 ± 0.4+ 28.8 ± 4.3++** 
Nine-month-old male mice were orchidectomized and then treated with vehicle (V), 17ß-estradiol (E), or DHT 
for 4 weeks. Sham-operated animals were also included, n = 7-8 in the WT groups; n = 4-6 in the ER«_/~ß"/- 
groups. Values are given as means ± SEM. **, P < 0.01 vs. orx + V; tt, P < 0.01; t, P < 0.05 vs. sham; ANOVA 
followed by Student-Newman-Keul's multiple-range test. 
Norland, Fort Atkinson, WI) operating at a resolution of 70 /xm 
as described (13). Trabecular BMD was determined ex vivo, with 
a metaphyseal pQCT scan of the distal femur. The scan was 
positioned in the metaphysis at a distance from the distal growth 
plate corresponding to 4% of the total length of the femur, and 
the trabecular bone region was defined as the inner 45% of the 
total cross-sectional area. Cortical bone parameters were deter­
mined ex vivo with a middiaphyseal pQCT scan of the femur. 
MicroCT. MicroCT analysis was done on the distal femur by using 
a Skyscan 1072 scanner (Skyscan N.V.) and imaged with an x-ray 
tube voltage of 50 kV withal -mm aluminum filter. The scanning 
angular rotation was 185° and the angular increment was 0.675°. 
Pixel size was 4.56 /xm a nd magnification was X60. Recon­
structed datasets were segmented into binary images by usin g 
adaptive local t hresholding (21). Trabecular bone distal of the 
growth plate was selected for analysis within a conforming 
volume of interest (cortical bone excluded), commencing at a 
distance of 100 jiim f rom the growth plate and extending a 
further longitudinal distance of 2.3 mm in the proximal direction. 
The number of slices was 500, each with the same thickness as 
the pixel size, 4.56 /xm. Trabecular thickness and separation were 
calculated by the sphere-fitting local thickness method (22). 
Trabecular bone thickness measurement was calibrated by using 
aluminum foils of 20- and 250-jitm thicknes s (Advent Research 
Materials, Oxford). For both foils the tolerance of the stated 
thickness was ±10%. Paired foils of each thickness were 
scanned, and CT images of them were reconstructed and seg­
mented by using exactly the same steps and parameters as 
applied to all the mouse femurs in this study. Aluminum provides 
a suitable material for calibration of microCT measurement of 
bone-structure thickness. The x-ray opacity of aluminum is 
slightly greater than that of cortical bone. However, aluminum 
is m aterially uniform on a micrometer scale, unlike hydroxy-
apatite preparations at densities similar to cortical bone, which 
is important for precise calibration of thicknesses of m icrons to 
tens of microns. 
Dual X-Ray Ab sorptiometry. Measurement of areal BMD of the 
middiaphyseal area of femur ex vivo was performed with the 
Norland pDEXA SABRE (Norl and) and the SABRE RE SEARCH 
software (v3.6) as described (13). 
Mechanical Testing. The tibia was subjected to mechanical testing 
by using Mechanical Tester 8841 (Instron, Canton, MA). Three-
point bending force was measured by placing the bone horizon­
tally with the anterior surface upward and applying a pressing 
force vertically to the midshaft of the bone. Each bone was 
compressed with a constant speed of 2 mm/min until failure. The 
breaking force (maximal load) was defined as the bending load 
at failure. 
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Serum Parameters. Serum osteocalcin levels were measured by 
using a monoclonal antibody raised against human osteocalcin 
(Rat-MID osteocalcin ELISA, Osteometer Biotech, Herlev, 
Denmark). The sensitivity of the osteocalcin assay was 21.1 
ng/ml and intra- and interassay coefficients of variation (CVs) 
were <10%. Serum insulin-like growth factor I ( IGF-I) levels 
were measured by double-antibody, IGF-binding protein-
blocked RIA (23). 
Statistical Analysis. Data are expressed as mean ± SEM. In 
general, statistical significance (P < 0.05) was determined by 
using one-way ANOVA followed by S tudent-Newman-Keul's 
multiple-range test. Two-way ANOVA, in which ERa-/~ and 
ERß~'~ were regarded as separate treatments, followed by 
Student-Newman-Keul's multiple-range test, was used for the 
analyses of the endosteal and periosteal circumferences. Linear 
regression analyses were performed with serum IGF-I as the 
independent variable and cortical or trabecular bone parameters 
as the dependant variable. Pearson's correlation coefficient (r) 
was calculated. Student's t tests were used to analyze data from 
the linear-regression analyses, and P < 0.05 was considered 
significant. 
Results 
Effect of Orchidectomy in WT Mice. As expected, the weights of the 
seminal vesicles and the ventral prostate were reduced by orx in 
the WT mice (Table 1). Furthermore, orx resulted in a reduction 
of both tvBMD, as measured by p QCT, and bone volume, as 
measured by microCT in the metaphyseal region of femur; Figs. 
1-3), and cortical [bone mineral content (BMC), cross-sectional 
area, thickness, and density as measured by a middiaphyseal 
pQCT scan of the femur; Table 2] bone parameters. These 
orx-induced structural bone changes were associated with re­
duced mechanical strength, as measured by using three-point 
bending of the tibia (Fig. 4) and with increased serum levels of 
osteocalcin (Fig. 5/4). 
Effect of 17/3-Estradiol and DHT in Orchidectomized WT Mice. Seminal 
vesicles and the ventral prostate. The DMT dose used (45 /xg/day) 
was physiological because it completely prevented the orx-
induced loss of weight of the seminal vesicles and the ventral 
prostate in W T mice (Table 1). As expected, 17ß-estradiol did 
not prevent the orx-induced weight loss of the seminal vesicles or 
the ventral p rostate (Table 1). 
Trabecular bone. The capacity of 17/3-estradiol a nd DHT to pre­
serve the trabecular and cortical bone was then compared. The 
tvBMD was first measured in the metaphyseal region of the 
distal femur by using pQCT. Both 17jß-estradiol and DHT 
prevented orx-induced reduction in tvBMD in WT mice (Fig. 1). 
To investigate whether 17ß-estradiol and DHT prevent the 
orx-induced loss of trabecular bone by similar alterations in the 
trabecular bone microarchitecture, 3D microCT analyses of 
the metaphyseal reg ion of distal femur were performed. Treat-
Movérare et al. 
Table 2. Cortical parameters 
Parameter Sham orx + E orx + DHT 
BMC, mg/mm 
WT 1.23 ± 0.03 1.07 ± 0.03t+ 1.26 ± 0.05** 1.01 ± 0.03t+ 
ER«-/- 1.04 ± 0.04 1.00 ± 0.02 0.92 ± 0.04 0.97 ± 0.03 
ERa~/-ß-/- 1.03 ± 0.05 0.98 ± 0.08 0.98 ± 0.05 0.99 ± 0.02 
Density, mg/mm3 
WT 1.168 ± 0.006 1.128 ± 0.010n 1.184 ± 0.007** 1.111 ± 0.009++ 
ERtf-/- 1.135 ± 0.010 1.134 ± 0.006 1.116 ± 0.016 1.134 ± 0.010 
ER a-'-ß-'- 1.130 ± 0.011 1.108 ± 0.020 1.100 ± 0.013 1.126 ± 0.009 
Cross-sectional area, mm2 
WT 1.06 ± 0.02 0.94 ± 0.02+ 1.06 ± 0.04** 0.91 ± 0.02++ 
ER«-/- 0.91 ± 0.03 0.89 ± 0.01 0.82 ± 0.03 0.85 ± 0.02 
ER«-/~ß-/- 0.91 ± 0.04 0.88 ± 0.06 0.89 ± 0.03 0.88 ± 0.02 
Thickness, ^m 
WT 200 ± 4 177 ± 3+t 200 ± 4** 171 ± 4tt 
ER«-/- 183 ± 5 183 ± 2 175 ± 5 177 ± 5 
ERa~/-ß-/- 188 ± 5 175 ± 10 176 ± 4 183 ± 2 
Cortical bone parameters as determined by using a middiaphyseal pQCT scan of the femur. Nine-month-old 
WT, ERa-/~, and ERa-/~ß-/~ male mice were orchidectomized and then treated with vehicle (V), 17/3-estradiol 
(E), or DHT for 4 weeks. Sham-operated animals were also included, n = 7-8 in the WT and ERa"/_ groups; n = 
4-6 intheERa-/~ß-/~ groups. Values are given as means ± SEM. **, P< 0.01 vs. orx + V; tt, P< 0.01; t, P< 0.05 
vs. sham; ANOVA followed by Student-Newman-Keul's multiple-range test. 
ment with 17/3-estradiol prevented orx-induced reduction in the 
trabecular bone volume as a result of both preserved number and 
preserved thickness of trabeculae in WT mice (Figs. 2 and 3). 
DHT treatment also preserved the trabecular bone volume but, 
in contrast to 17/3-estradiol treatment, it was only caused by 
preserved trabecular number, whereas the trabecular thickness 
was unaffected by D HT treatment (Figs. 2 and 3). Thus, even 
though both 17/3-estradiol, by act ivation of ERs, and DHT, by 
activation of the AR, exert trabecular bone-sparing effects, it is 
clear that the underlying mechanisms of action differ as the 
trabecular thickness is increased by 17/3-estradiol but not by 
DHT. 
Cortical bone. Cortical bone parameters were first measured by a 
middiaphyseal pQCT scan of the femur. Cortical BMC was 
preserved by 17 /3-estradiol but not by DHT in orx WT mice 
sham 
orx + V 
orx  +1  
orx + DHT 
2Ö0 ~ 
Fig. 1. tvBMD of the distal metaphyseal area of femur measured by using 
pQCT. Nine-month-old male mice were orchidectomized and then treated 
with vehicle (V), 17/3-estradiol (E), or DHT for 4 weeks. Sham-operated animals 
were also included, n = 7-8 in the WT groups; n = 4-6 in the ERa~/_ß-/~ 
groups. Values are given as means ± SEM. **, P<0.01 vs. orx + V; tt, P<0.01; 
t, P < 0.05 vs. sham; ANOVA followed by Student-Newman-Keuls multiple-
range test. 
(Table 2). The stimulatory effect of 17/3-estradiol was due both 
to an increased cortical v olumetric BMD and to an increased 
cortical cross-sectional area, the latter as a result of an effect on 
cortical th ickness in orx mice (Table 2). DHT did not have any 
effect on cortical bone parameters in these 10-month-old orx 
mice (Table 2). The effects on cortical bone were also analyzed 
by a middiaphyseal dual x-ray absorptiometry scan of the femur, 
confirming the pQCT findings that 17ß-estradiol but not DHT 
preserved the amount of cortical bone in orx WT mice (cortical 
areal BMD: ovx plus 17ß-estradiol, +12.1 ± 2.7% over vehicle, 
P < 0.05; orx plus DHT, +1.1 ± 5.2% over vehicle, not 
significant; ANOVA, followed by Student-Newman-Keul's 
multiple-range test). 
Mechanical strength. Mechanical strength, as measured by us ing 
three-point bending of the tibia and given as maximal load, was 
preserved by 17/3-estradiol , b ut not by DHT, in o rx WT mice 
(Fig. 4). The qualitative bone parameter elastic modulus was not 
affected by 17/3-estradiol or DHT treatment in either genotype 
(data not shown). 
Serum osteocalcin and IGF-I. DHT, but not 17/3-estradiol, prevented 
the increase in osteocalcin that followed orchidectomy (Fig. 5A). 
17ß-Estradiol increased, whereas DHT slightly decreased, serum 
levels of IGF-I in orx WT mice (Fig. 5B). Furthermore, serum 
IGF-I levels were positively correlated with all the cortical 
(BMC, cortical volumetric BMD, cross-sectional area, thickness, 
maximal load) and trabecular (trabecular thickness) bone pa­
rameters that were specifically preserved by 17/3-estra diol but 
not by DHT (Table 3). 
Effect of 17/3-Estradiol and DHT in Orchidectomized ERa_/~ß_/_ Mice. 
Orx resulted in reduced trabecular bone parameters, whereas the 
cortical bone parameters were mainly unaffected by orx in 
ERor/-/3-/~ mice (Figs. 1-3 and Table 2). 
Effect of 17ß-estradiol. The effect of 17/3 -estradiol on tvBMD is 
mediated by ERa as no effect was seen in ERor/_ß~/_ or 
ERaT/_ mice (Fig. 1, data not shown, and ref. 16). Furthermore, 
no effect of 17/3-estradiol was seen on any other trabecular or 
cortical bone parameter in orx ERor^ß-7- mice (Figs. 2-4 and 
Table 2). Statistical analyses performed independently on results 
from ERa+/+ and ERa-/~ mice, respectively, showed that the 
ERa-mediated increase in cortical thickness of femur in orx mice 
was caused by a decrease in the endosteal circumference (-4.9 ± 
Movérare et al. PNAS I Novembern, 2003 | vol.100 | no. 23 | 13575 
fifkvf"-
Fig. 2. Trabecular bone volume (-4), trabecular number (ß), and trabecular 
thickness (Q as measured by microCT. Nine-month-old male mice were orchi-
dectomized and then treated with vehicle (V), 17ß-estradiol (E), or DHT for 4 
weeks. Sham-operated animals were also included, n = 7-8 in the WT groups; 
n = 4-6 in the ERa - / -ß~ / -  groups. Values are given as means ± SEM. **, P < 
0.01 vs. or x + V; tt, P < 0.01; t, P < 0.05 vs. sham; ANOVA followed by 
Student-Newman-Keul's multiple-range test. 
1.6%; P < 0.05 two-way ANOVA, followed by Student-
Newman-Keul's multiple-range test), whereas the periosteal 
circumference was not affected. Serum levels of osteocalcin and 
IGF-I were also not altered by 17ß-estradiol in ERa_/"/3~/_ 
mice (Fig. 5). 
Effect of DHT. All the DHT effects seen in orx WT mice were also 
present in o rx ERaT/~ß~/" mice. Comparison of the effect of 
DHT in WT versus ERa~'~ß~'~ mice demonstrated that DHT 
produced a greater effect in ERa-/~/3~/- mice than in WT mice 
for the weight of the ventral prostate, the trabecular bone 
volume, the tvBMD, and the trabecular number (P < 0.05, 
Student's t test; Table 1 and Figs. 1 and 2). A similar but not 
significant tendency was also seen for the weight of seminal 
vesicles (P = 0.073; Table 1). 
Discussion 
The role of estrogens in the regulation of the adult skeleton in 
females is well e stablished, whereas the relative importance of 
Fig. 3. Representative microCT scans. Nine-month-old male mice were 
orchidectomized and then treated with vehicle (V), 17ß-estradiol (E), or DHT 
for 4 weeks. Sham-operated animals were also included. 
estrogens versus androgens in the regulation of bone metabolism 
in adult males remains unclear. We and others have demon­
strated that orx-induced trabecular bone loss can be prevented 
by testosterone, DHT, and 17/3-estradiol in adult rodents (16,17, 
20,24-26). The present study, by using both pQCT and microCT, 
confirms our previous reports that ERa but not ER/3 is of 
importance for the trabecular bone-sparing effect of estrogens in 
male mice (16, 17). Furthermore, the trabecular bone-sparing 
sham 
orx 4- V 
I 1 orx 4- E 
orx + DHT 
<3 1.v> 
Fig. 4. Maximal load (N), a measurement of the strength of the bone, as 
measured by using three-point bending of the tibia. Nine-month-old male 
mice were orchidectomized and then treated with vehicle (V), 17ß-estradiol 
(E), or DHT for 4 weeks. Sham-operated animals were also included, n = 7-8 
in the WT groups; n = 4-6 in the ERor/-ß~/_ groups. Values are given as 
means ± SEM. **, P< 0.01 vs. orx + V; tt, P< 0.01 vs. sham; ANOVA followed 
by Student-Newman-Keul's multiple-range test. 
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Fig. 5. Serum osteocalcin as measured by ELISA (A) and IGF-I as measured by 
RIA (B). Nine-month-old male mice were orchidectomized and treated with 
vehicle (V), 17ß-estradiol (E), or DHT for 4 weeks. Sham-operated animals were 
included, n = 7-8 in the WT groups; n = 4-6 in the ERa-/~ß-/~ groups. Values 
are given as means ± SEM. **, P < 0.01; *, P < 0.05 vs. orx + V; tt, P < 0.01; 
t, P< 0.05 vs. sham; ANOVA followed by Student-Newman-Keul's multiple-
range test. 
effect of estradiol is only mediated by ERa and not by the AR. 
In addition, we directly show that the AR-activator DHT in­
creased the amount of trabecular bone independent of ERs. 
These findings, together with recently published data by Sims et 
al. (18), clearly demonstrate that in c ontrast to what has been 
concluded from in vitro stu dies (19, 26), no functional cross-
reactivity exists between ERs and AR in vivo. 
pQCT analyses of tvBMD demonstrated that the trabecular 
bone-sparing effect of AR activation and ERa activation was of 
the same magnitude. However, more detailed analysis of 
the trabecular bone microarchitecture, with high-resolution 
microCT, demonstrated that ER but not AR activation pre-
Table 3. Correlation with serum IGF-I and different bone 
parameters 
Compartment Measurement r 
Trabecular Volumetric BMD 0.06 
Trabecular thickness 0.40** 
Trabecular number -0.22 
Cortical BMC 0.59*** 
Volumetric BMD 0.53*** 
Cross-sectional area 0.58*** 
Thickness 0.45*** 
Maximal load 0.40** 
Elastic modulus -0.1 
Correlations of al animals (n = 50) included in the study were calculated by 
using Pearson's correlation coefficient (r). **, P < 0.01; ***, P < 0.001. 
DHT Estrogen 
AR ER« 
Cortical 
BMP Number 
Cortical 
Thickness 
Trabecular 
Thickness 
Fig. 6. Differential effects on bone of ERa and AR activation in adult male 
mice. Activation of ERa preserves the trabecular number, trabecular thickness, 
cortical thickness, and cortical density, whereas activation of AR preserves only 
the trabecular number after orx. 
served the trabecular thickness, whereas AR activation only 
preserved the number of trabeculae (Fig. 6). These findings show 
that AR activation and ER activation regulate the amount of 
trabecular bone by different mechanisms of action. This notion 
is further supported by the different results of 17/3-estradiol and 
DHT treatment for 4 weeks on serum levels of osteocalcin. One 
possible explanation for this is that the estrogen e ffect may be 
mediated not only by decreased bone turnover, but also by 
increased bone formation, whereas DHT treatment only de­
creases the bone turnover. In contrast to ovariectomized mice, 
limited studies have been done on the effect of estradiol on 
serum levels of osteocalcin and bone turnover in orchidecto­
mized mice. In this regard, we have found that estradiol treat­
ment of orchidectomized mice did not reduce serum levels of 
osteocalcin (16, 17). Our present findings on serum osteocalcin 
levels are consistent with our previous data. Moreover, we have 
found no evidence for reduced bone formation in 17ß-estradiol-
treated orchidectomized mice as studied by histomorphometric 
analyses (17). Thus, neither serum levels of osteocalcin nor bone 
formation, parameters measured by dynamic histomorphometry, 
were reduced by estr adiol treatment in o rchidectomized mice. 
One limitation of the present study is that no marker of bone 
resorption was measured. 
An interesting difference between the effect of ER activation 
and AR activation was also seen on the cortical bone parameters. 
17/3-Estradiol preserved the amount of cortical bone (cortical 
cross-sectional area and thickness), the density of the cortical 
bone, and the mechanical strength of the cortical bone. In g» 
contrast, no effect by DHT treatment was seen on any of these g 
cortical bone parameters. The ERa-induced increase in cortical jg 
thickness compared with orx mice was caused by a reduced 
endosteal circumference, whereas the periosteal circumference 
was unaffected. We and others have recently demonstrated that lig! 
endocrine, liver-derived IGF-I is an important regulator of the 
amount of cortical bone and the mechanical strength of cortical 
bone (27, 28). In t he present study, ER activation, but not AR 
activation, resulted in increased serum levels of IGF-I, which in 
turn were positively correlated with several cortical bone pa­
rameters, suggesting that the effect of 17/3-estradiol on these 
cortical bone parameters might be mediated by an induction of 
the amount of endocrine IGF-I. Thus, we propose that ER 
activation, but not AR activation, results in increased serum 
levels of IGF-I, which in turn increase the amount of cortical 
bone in orx mice. 
The tvBMD and the trabecular bone volume were not corre­
lated with serum IGF-I. However, microCT analyses showed that 
the thickness of the trabeculae, but not the number of trabeculae, 
was correlated with serum IGF-I; and because it was the 
thickness of the trabeculae that was specifically increased by 
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17/3-estradiol, but not by DHT, one may speculate that 17ß-
estradiol increases the trabecular thickness by an induction of 
serum IGF-I levels. 
The above-mentioned results of sex steroid receptor specificity 
in bone, derived from the experiment by using replacement 
therapy with 17/3-estradiol or DHT to orx mice, are supported by 
our observations of the effect of orx in ER double-inactivated 
mice. Orx of these mice resulted in reduced tvBMD but unaf­
fected cortical bone parameters, indicating that the trabecular 
bone is, at least in p art, maintained by activation of the AR in 
gonadally intact, ER double-inactivated male mice, whereas AR 
activation in t hese mice does not influence cortical bone. 
For some androgen-regulated parameters the effect of DHT 
was greater in ERa-/~ß~/_ mice than in WT mice, which may 
be because of increased AR expression in ERar/-/3-/~ mice. AR 
expression was not analyzed in the present study. Sims et al. (18), 
however, have shown that AR expression was increased in 
ERa-inactivated mice. 
In conclusion, ER activation results in preserved thickness and 
number of trabeculae and preserved thickness and volumetric 
density of cortical bone; these effects of 17/3-estradiol cannot be 
mediated by means of the AR (Fig. 6). In contrast, AR activation 
results in a specific preservation of the number of trabeculae, 
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Additive Protective Effects of Estrogen and Androgen Treatment on 
Trabecular Bone in Ovariectomized Rats 
Åsa Tivesten.1 Sofia Movérare-Skrtic,2 Andrei Chagin,3 Katrien Ven ken.4 Phil Salmo n,5 Dirk V anderschueren,4 
Lars Sävendahl.3 Agneta Holmäng,1 and Claes Ohlsson2 
ABSTRACT: Both ER and AR activation regulates trabecular bone mass. We show that combined estrogen 
and androgen treatment results in additive protection of trabecular bone in OVX rats. This may in pa rt be 
attributable to the effect of AR activation to attenuate the inhibitory effect of ER activation on bone formation. 
Introduction: Sex steroids are important regulators of trabecular bone mass. Both estrogen receptor (ER) and 
androgen receptor (AR) activation results in increased trabecular bone mass. The aim of this study was to investigate 
if combined estrogen and androgen treatment might be beneficial in the treatment of trabecular bone loss. 
Materials and Methods: Twelve-week-old female rats were ovariectomized (OVX) and treated with vehicle (V), 
17ß-estradiol (E2; ER activation), dihydrotestosterone (DHT; AR activation), or the combination (E2 + DHT) for 6 
weeks. The skeletal phenotype was analyzed by pQCT, /xCT, histomorphometry of growth plates, and serum levels 
of biochemical bone markers. 
Results: Both E2 (+121% over V) and DHT (+34%) preserved the trabecular volumetric BMD (tvBMD) in OVX 
rats. The effect of E2 and DHT on tvBMD was additive, resulting in a 182% increase over V in the rats given E2 + 
DHT. /xCT analyses of the trabecular bone microstructure revealed that the effect of E2 and DHT was additive on 
the number of trabeculae. E2 treatment reduced serum markers of both bone resorption (collagen C-terminal 
telopeptide) and bone formation (osteocalcin), indicating reduced bone turnover. Addition of DHT to E2 treatment 
did not modulate the effects of E2 on the marker of bone resorption, whereas it attenuated the inhibitory effect of E2 
on the bone formation marker, which might explain the additive protective effect of E2 and DHT on trabecular bone 
mass. In contrast, DHT partially counteracted the suppressive effect of E2 on longitudinal bone growth and the 
E2-induced alterations in growth plate morphology. 
Conclusions: These findings show that combined estrogen and androgen treatment results in additive protective 
effects on trabecular bone in OVX rats. Our data suggest that a combined treatment with selective ER and AR 
modulators might be beneficial in the treatment of osteoporosis. 
J Bone Miner Res 2004;19:1833-1839. Published online on August 23, 2004; doi: 10.1359/JBMR.040819 
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INTRODUCTION 
OSTEOPOROSIS IS A COMMON disorder characterized by reduced bone mass and an increased susceptibility to 
fractures. Traditionally it has been considered a condition of 
postmenopausal and elderly women, but osteoporosis in 
men is now recognized as an increasingly important public 
health issue.*n Sex steroids are important for the mainte­
nance of both the female and the male skeleton/1-3* How­
ever, the relative contribution of androgens versus estrogens 
in the regulation of the skeleton is unclear. The effects of 
testosterone can be exerted either directly through the an-
The authors have no conflict of i nterest. 
drogen receptor (AR) or indirectly through aromatization to 
estrogens and further through estrogen receptor (ER)a 
and/or ERß.(4> All three of these sex steroid receptors are 
expressed both in growth plate cartilage and in bone.(5-9) 
ERa is the major ER responsible for the trabecular bone-
sparing effect of estrogen both in m ales and females/10-13* 
Studies using ER-inactivated mice have shown that ER/3 
modulates ERa-mediated gene transcription, s upporting a 
"Ying Yang" relationship between ERa and ER/3 in the 
regulation of bone mass in female mice/,4-l7) The non-
aromatizable androgen dihydrotestosterone (DHT) in­
creases trabecular bone mass in mice devoid of ERs, show­
ing that the AR. besides ERs, has the capacity to preserve 
trabecular bone in gonadectomized mice/11 8) Some in 
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vitro studies have shown that ER«, ERß, and AR can 
transmit the antiapoptotic effect of sex steroids with similar 
efficiency, irrespective of whether the ligand is an estrogen 
or an androgen."9-20 However, several in vivo studies do 
not support the notion that es trogens have important AR-
mediated phy siological effects on trabecular b one mass or 
the co ncept that non-aromatizable androgens exert bone-
sparing effects on trabecular BMD through direct activation 
of the ERs.(l0"l2-,8-22~24) Furthermore, it was recently 
shown that th e in vivo effect of ER activation on bone is 
distinct fr om the effect of AR activation/11-12"25' Because 
these two pathways are distinct from each other, one may 
speculate that a combined treat ment with selective ER and 
AR modulators might be beneficial in the treatment of 
osteoporosis.02) In this study, w e have examined the effects 
of combined estrogen and androgen treatment on trabecular 
bone mass and longitudinal bone growth in ovariectomized 
(OVX) rats. 
MATERIALS AND METHODS 
Animals 
Female Sprague-Dawley rats were purchased from Scan-
bur BK AB (Sollentuna, Sweden). The animals were housed 
in a temperature- and humidity-controlled room with a 6:00 
a.m. to 6:00 p.m. light c ycle and allowed a soy-free diet 
containing 0.7% of calcium and 0.5% of pho sphorus (R70; 
Lactamin AB, Kims tad, Sweden) and tap water ad libitum. 
All procedures were approved by the ethics committee at 
Göteborg University a nd conformed to th e National Insti­
tutes of Health G uide for the Care and Use of Laboratory 
Animals. 
Study protocol 
The animals were randomly divided into five groups: 
sham operation + vehicle treatment (sham, n = 12), OVX 
+ vehicle treatment (V, n = 10), OVX 4- 17/3-estradiol 
treatment (E2, n = 11), OVX + dihydrotestosterone treat­
ment (DHT, n = 10), and OV X + combined E2 a nd DHT 
treatment (E 2 + DHT, n = 11). At 12 weeks of age (body 
weight, 251 + 2 g), the rats were either sham-operated or 
OVX under isoflurane anesthesia (Baxter Medical AB, 
Kista, Sweden), and small silastic implants were placed 
subcutaneously in the cervical region. The silastic implants 
were prepared as previously described,'25> releasing 2.5 
/xg/day of E 2 or 40 /xg/day of DHT. Vehicle-treated animals 
received an empty implant and the E2 + DHT group re­
ceived both a n E2 and a DHT implant. 17/3-estradiol and 
5a-dihydrotestosterone were obtained from Sigma Chemi­
cal. After 3 weeks of treatment, blood sa mples for subse­
quent serum analyses of collagen C-terminal telopeptide, 
osteocalcin, and insulin-like growth factor-I (IGF-I) were 
collected from the tail. After 6 weeks of treatment, the 
animals were killed by excision of the heart under isoflurane 
anesthesia, and bo nes were collected. 
PQCT 
pQCT was performed with the Strate c pQCT XCT Re­
search M (Norland; v5.4B) operating at a resolution of 70 
/xm.(26) Trabecular volumetric BMD (tvBMD) was deter­
mined ex vivo, with a metaphyseal pQCT scan of the distal 
femur, and defined as the inner 45% of the total cross-
sectional area. The scan was positioned in the metaphysis at 
a distance from the distal growth plate corresponding to 7% 
of the total length of t he femur. Cortical bone parameters 
were determined ex vivo with a mid-diaphyseal pQCT scan 
of the f emur. The CVs for these measurements were <2%. 
ILCT 
/xCT analy sis was done on the distal femur using the 
Skyscan 1072 scanner (Skyscan N.V., Aartselaar, Belgium), 
imaged with an X-ray tube voltage of 70 kV and current 100 
/xA, with a I-m m aluminum filter. F emurs were taken from 
alcohol storage and dried in air for 1 h before scanning. The 
scanning angular rotation was 185°, and the angular incre­
ment was 0.45°. The voxel size was 7.66 /xm isotropically 
and the magnification was X37. Data sets were recon­
structed using a modified Feldkamp algorithm'27' and seg­
mented into binary images using adaptive local threshold-
ing.'28) Trabecular bone distal to the growth plate was 
selected for analysis within a conforming volume of interest 
(cortical bone excluded) commencing at a distance of 1.5 
mm from the growth plate, and extending a further longi­
tudinal distance of 2.5 mm in the pr oximal direction. A total 
of 330 image slices was analyzed for each femur. Trabec­
ular thickness and separation were calculated by the sphere-
fitting local thickn ess method.(29) Measurements of trab ec­
ular thickness were calibrated by scanning and analyzing 
three aluminum foils with th icknesses of 50, 125 and 250 
/xm. 
Quantitative histology of growth plates 
The length of the femur and tibia was measured ex vivo 
using vernier calipers (Helios; Promet CEJ AB, Eskilstuna, 
Sweden). Quantitative histology of the growth plate was 
analyzed as previously described.'30' with sl ight modifica­
tions. Briefly, the right proximal tibia was fixed in 4% 
paraformaldehyde, decalcified, and embedded in paraffin. 
Sections (5 /xm thick) were stained with Alcian blue/van 
Gieson. Images were captured using a Nikon Eclipse E800 
light microscope connected to a Hamamatsu digital camera 
C4742-95 and a computer. All histological measurements 
were performed in th e central two-thirds of the growth plate 
sections at X200 magnification using Olympus Microimage 
software (version 4.0: Olympus Optical. Hamburg, Ger­
many). The height of the g rowth plate was calculated as an 
average of 25 measurements per growth plate. The number 
of proliferative and hypertrophic cells was counted in 15 
columns per growth plate and averaged for each growth 
plate. Hypertrophic chondrocytes were defined by a h eight 
of >7 /xm. The height of the terminal hypertrophic chon­
drocyte, the cell in the last intact lacuna, was measured in 25 
different co lumns per growth plate and averaged. 
Serum parameters 
Serum levels of collagen C-terminal telopeptide, as a 
marker of bone resorption, were measured using an ELISA 
(RatLaps; Nordic Bioscience Diagnostics, Herlev, Den­
mark). The intra- and interassay CVs were <11%. Serum 
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TABLE 1. BODY WEIG HT A ND U TERINE W EIGHT 
Sham V E2 DHT E2 + DHT 
Body weight (g) 
Uterine weight (mg) 
286 ± 6 
529 ± 48 
330 
145 
± 9* 
± 10* 
268 
923 
± 4 « t  
± 116** 
329 ± 10»* 
186 ± 16«* 
277 ± 4'! 
867 ± 37»*5 
Twelve-week-old female rats were OVX and treated with veh icle (V). 17/3-estradiol (E2). dihydrotestosterone (DHT). or the combination (E, + DHT) 
for 6 weeks. Sham-operated animals w ere also included (Sham), n = 10-12. Values are given as means ± SE. 
* p < 0.05 vs. sham. 
fp < 0.05 vs. V. 
* p < 0.05 vs. E 2. 
9 p < 0.05 vs. DHT (ANOVA followed by Fisher's pro tected least significance difference test ). 
osteocalcin levels were measured using an IRMA (Immu-
topics, San demente, CA, USA). The intra- and interassay 
CVs were <5%. Serum was assayed for IGF-I by a double 
antibody IGF binding protein-blocked RIA (Mediagnost, 
Tubingen, Germany). 
Statistical analysis 
A p value of <0.05 was considered statistically signifi­
cant. All statistical comparisons between the live groups 
were performed using a one-way ANOVA and posthoc 
testing with Fisher's protected least significance difference 
test. A line ar regression analysis was performed with serum 
IGF-I a s the independent variable and height of hypertro­
phic chondrocytes as the dependent variable, and Pearson's 
correlation coefficient (r) was calculated. 
RESULTS 
Body weight and uterine weight 
As expected, t he uterine weight was clearly reduced by 
OVX. The E2 dose chosen prevented the loss in uterine 
weight and even resulted in higher uterine weight in the E 2 
group compared with sham rats (Table 1). DHT treatment 
did not significantly affect the uterine weight. OVX resulted 
in an increased body weight, which was prevented by E2 but 
not by DHT treatment (Table 1). 
tvBMD 
tvBMD was measured in the metaphyseal region of the 
distal femur using pQCT. OVX resulted in a pronounced 
loss of tvBMD (—45%, p < 0.01, Fig. 1) compared with 
sham rats. E2 treatment of the OVX rats fully prevented the 
OVX-induced trabecular bone loss (+121% over OVX ve­
hicle) and even resulted in slightly higher tvBMD than 
observed in s ham rats. DHT treatment increased (+34%) 
the tvBMD compared with vehicle-treated OVX rats, but it 
only partially prevented the OVX-induced lo ss of tvBMD. 
Interestingly, the protective effect of E2 and DHT was 
additive, resulting in a 182% increase in tvBMD of the rats 
given E2 + DHT compared with OVX (Fig. 1). In contrast, 
no interaction between E2 and DHT was seen for the cortical 
bone parameters as measured by a di aphyseal pQCT section 
of th e femur (data not shown). 
Structural parameters of trabecular bone measured by 
p.CT 
To investigate t he effects o f the different treatments on 
trabecular bone microarchitecture, 3D /xCT analyses of the 
800 
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Sham V E2 DHT E2+DHT 
FIG. 1. tvBMD of the distal metaphyseal area of the femur measured 
using pQCT. Twelve-week-old female rats were OVX and treated with 
V. E2. DHT. or E2 + DHT for 6 weeks. Sham-operated animals were 
also included (sham), n = 10-12. Values are given as means ± SE. 
ap < 0.05 vs. sham: hp < 0.05 vs. V; cp < 0.05 vs. E2: dp < 0.05 vs. 
DHT (ANOVA followed by Fisher's protected least significance dif­
ference test). 
FIG. 2. (A) BV/TV. (B) Tb.Th. and (C) Tb. N as measured by / iCT. 
Twelve-week-old female rats were OVX and treated with V. E2. DHT. 
or E2 + DHT for 6 weeks. Sham-operated animals were also included 
(sham), n = 10-12. Values are given as means ± SE. ap < 0.05 vs. 
sham; bp < 0.05 vs. V; cp < 0.05 vs. E2:dp < 0.05 vs. DHT (ANOVA 
followed by Fisher's protected least significance difference test). 
metaphyseal region of the distal femur were performed. 
Ovariectomy resulted in a pronounced reduction in trabec­
ular bone volume, mainly as a result of a reduced number of 
trabeculae, whereas no major e ffect was seen on the thick­
ness of the trabeculae (Figs. 2 and 3). E2 treatm ent fully and 
DHT treatment partially prevented the OVX-induced reduc­
tion in trabecul ar bone volume (Fig. 2A). Both E2 and DHT 
increased the number of trabeculae, whereas only E2 in­
creased the th ickness of the trabeculae (Figs. 2B and 2C). 
The effect of E- > and DHT on trabecular bone volume was 
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Sham 
E2+DHT 
FIG. 3. Representative jiCT scans of OVX rats treated with V. E2, 
DHT. or E2 + DHT for 6 weeks. Sham-operated animals were also 
included (sham). 
additive and mainly caused by an additi ve effect on trabec­
ular number as shown by significantly higher values for 
these p arameters in the E2 + DHT group compared with 
both the E2 and the DHT groups (Figs. 2 and 3). 
Serum hone markers 
To investigate the mechanism behind the additive effect 
of E 2 and DHT on trabecular bone mass, serum bone mark­
ers associated with bone resorption (collagen C-terminal 
telopeptide, RatLaps) and bone formation (osteocalcin) 
were measured on s erum samples collected 3 weeks after 
the initiation o f treatment. OVX resulted in a significant 
increase in collagen C-terminal telopeptide levels in serum 
compared with sham (Fig. 4A: p < 0.05). E2 a s well a s E2  
4- DHT reduced serum levels of collagen C-terminal te­
lopeptide. whereas no significant effe ct w as seen for DHT 
alone (Fig. 4A). Serum levels of osteocalcin were increased 
3 weeks after OVX (Fig. 4B; p < 0.05). E2 treatment 
resulted in a pronounced reduction of serum osteocalcin, 
whereas D HT treatment resulted in only a slight reduction 
in osteocalc in levels compared with vehicle-treated OVX 
rats. Animals with combined E2 + DHT treatment had 
higher levels of osteocalcin than E 2-treated rats (Fig. 4B). 
Longitudinal growth and growth plate morphology 
OVX resulted in an increased length of the tibia (Fig. 5). 
Compared with vehicle-treated OVX rats, E 2 treatment re­
tarded the lo ngitudinal growth of both the tibia and fe mur, 
whereas no effect was seen for DHT treatment alone. How­
ever, the addition of DHT to E2 partially counteracted the 
inhibitory eff ect of E2 on longitudinal growth of both the 
tibia and femur of OVX rats (Fig. 5). 
In an attempt to understand the mechanisms by which the 
different t reatments affect the longitudinal gro wth, quanti-
H Sham E2 DHT 
• V gj E2+DHT 
A B 13 =2 
FIG. 4. Serum levels of (A) collagen C-terminal telopeptide (Rat-
Laps) and (B) osteocalcin 3 weeks after OVX. Twelve-week-old fe­
male rats were OVX and treated with V. E2. DHT. or E2 + DHT. 
Sham-operated animals were also included (sham), n = 10-12. Values 
are given as means ± SE. ap < 0.05 vs. sham: hp < 0.05 vs. V : cp < 
0.05 vs. E2: ap < 0.05 vs. DHT (ANOVA followed by Fisher's 
protected least significance difference test). 
s Sham a DHT 
• V H E2+DHT 
Femur Tibia 
FIG. 5. Length of the femur and tibia. Twelve-week-old female rats 
were OVX and treated with V. E2, DHT, or E2 + DHT for 6 weeks. 
Sham-operated animals were also included (sham), n = 10-12. Values 
are given as means ± SE. ap < 0.05 vs. sham; hp < 0.05 vs. V: cp < 
0.05 vs. E2: dp < 0.05 vs. DHT (ANOVA followed by Fisher's 
protected least significance difference test). 
tative morphological studies of the growth plates in the 
proximal tibia were performed. E2 reduced the width of the 
growth plate compared with vehic le-treated OVX rats, and 
similarly, as seen for the lengths of the long bones, addition 
of D HT to E2 par tially counteracted the inhibitory effect of 
E2 (Table 2). The E2-induced reduction in growth plate 
width was associated with reductions in the number of 
proliferative and hypertrophic chondrocytes, a reduced ratio 
of proliferative/hypertrophic chondrocytes, and a cl ear re­
duction in the height of terminally d ifferentiated hypertro­
phic chondrocytes. The addition of DHT to E2 fully coun­
teracted the E2-induced reduction in the height of 
hypertrophic chondrocytes and partially counteracted the 
inhibitory effect on the number of proliferative chondro­
cytes. whereas it did not affect the number of hypertrophic 
chondrocytes (Table 2). Disturbances in longitud inal bone 
i> 
2 
O 
< Ü 
O 
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TABLE 2. GROWTH PLATE MEASUR EMENTS AND SE RUM IG F-I 
Sham V E2 DHT E, + DHT 
Growth plate width (fxm) 159 ±4 161 ± 4 124 ± 4»* 174 ± 5»" 135 ± 3»™ 
Proliferative chondrocytes 7.6 ± 0.2 7.8 ± 0.3 5.« ± 0.2*' 8.0 i 0.4* 6.0 ± 0.2*,,s 
(cells per column) 
Hypertrophic chondrocytes 5.1 ±0.3 5.2 ±0.1 4.3 ± «.2»' 5.8 ± 0.2»* 4.3 ± 0.2»,! 
(cells per column) 
Proliferative/hypertrophic 1.52 ± 0.07 1.50 ±0.08 1.19 ± 0.06«f 1.38 ± 0.06' 1.41 ± 0.07* 
HHC (I±M) 14.5 ± 0.4 14.6 ± 0.8 9.7 ± 0.4»* 15.4 ± 0.4* 13.7 ±0.5" 
Serum IGF-I (ng/ml) 689 ± 38 784 ± 66 550 ± 28»' 738 ± 56* 721 ± 30* 
Quantitative histology of the proximal tibial growth plate and serum levels of IGF-I. Twelve-week-old female rats were OVX and treated w ith vehicle 
(V). 17ß-estradiol (E2). dihydrotestosterone (DHT). or the combination (E, + DHT) for 6 weeks. Sham-operated animals were also included (Sham). Serum 
levels of IG F-I w ere analyzed after 3 weeks of treatment, n = 10-12. Values are given as means ± SE. 
* p < 0.05 vs. sham. 
fp < 0.05 vs. V . 
* p < 0.05 vs. E 2. 
ip < 0.05 vs. DHT (ANOVA fo llowed by F isher's protected least si gnificance difference test). 
HHC = height o f hypertrophic chondrocytes. 
growth and growth plate morphology are often associated 
with alterations in the growth hormone/IGF-I axis. E2 re­
duced serum levels of IGF-I, and this inhibitory effect on 
IGF-I was counteracted by the addition of DHT (Table 2). 
Interestingly, serum levels of IGF-I were strongly correlated 
to the height of the hypertrophic chondrocytes (r = 0.42, 
p < 0.001). 
DISCUSSION 
Osteoporosis is often associated with trabecular bone 
loss.(3,) Both ER activation and AR activation result in a 
preserved t rabecular bone mass/1112-24} This study showed 
that combined estrogen and androgen treatment results in 
additive protective effects on trabecular bone in O VX rats, 
suggesting that a combined targeting of both the ER and the 
AR pathway might be beneficial in the treatment of trabec­
ular bone loss. 
Loss of estrogens or androgens increases the rate of bone 
remodeling by removing restraining effects on osteohisto­
genesis and osteoclastogenesis and also causes a focal im­
balance between resorption and formation by prolonging the 
lifespan of osteoclasts and shortening the lifespan of osteo­
blasts/321 Although androgens, through the AR, and estro­
gens, through the ERs, can exert these effects, their relative 
contribution remains uncertain. Recent studies suggest that 
androgen action on trabecular bone depends on (local) aro-
matization of androgens into estrogens/4 33' However, at 
least in rodents, androgen action on cancellous bone can be 
directly mediated through AR activation, even in the ab­
sence of ERS.(IU2> This study confirms previous findings 
that both ER activation and AR activation have the capacity 
to preserve trabecular bone mass/" 1218,24} We also show 
that both E2 and DHT prevent the loss of trabeculae, 
whereas only E2 protects the thickness of the trabeculae, 
confirming a previous study using orchidectomized 
mice.(,2) 
In contrast to the male skeleton, the effect of androgens 
on the female skeletal homeostasis has not been well estab­
lished. However, hyperandrogenic women have increased 
trabecular BMD, suggesting that androgens also are of 
importance for the female skeleton/341 In this study, we 
showed that DHT treatment results in increased tvBMD in 
OVX rats, supporting the notion that AR activation is of 
importance for the regulation of not only the male but also 
the female skeleton. 
Interestingly, we show that combined estrogen and an­
drogen treatment results in a n additive protective effect on 
both the trabecular volumetric BMD, as measured by 
pQCT, and the trabecular bone volume, as measured by 
jxCT, in females. The additive effect of combined E2 and 
DHT treatment on the trabecular bone volume was caused 
by an increase in the number of trabeculae. 
The additive effect on trabecular bone mass and trabec­
ular number might partially be explained by the fact that 
DHT attenuated the inhibitory effect of E2 on bone forma­
tion, as indicated by the higher levels of osteocalcin in 
animals with combined E2 and DHT treatment compared 
with E2-treated rats, whereas it did not significantly influ­
ence the inhibitory effect of E2 on bone resorption markers. 
This would then result in an imbalance with bone formation 
exceeding bone resorption, resulting in increased bone 
mass. In line with these data, short-term administration of 
combined androgen and estrogen treatment reversed the 
inhibitory effects of estrogen on bone formation markers in 
postmenopausal women, whereas serum markers of bone 
resorption were unchanged/351 Our experimental results, 
showing additive effects on trabecular bone and similar 
alterations of serum bone markers as seen in the clinical 
study, may suggest that combined ER and AR activation 
could result in an additive effect on trabecular bone mass 
also in the clinical setting. 
The dose of DHT used in this study was selected accord­
ing to our previous dose-response studies in orchidecto­
mized male rats, and we chose a dose that resulted in 
prostate weight and seminal vesicle weight of the same 
magnitude as seen in sham-operated rats/25) The selected 
dose of E2 reversed the OVX-induced loss in uterine weight 
and even resulted in a higher uterus weight in E2-treated 
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compared with sham rats. Thus, the additive effects on 
trabecular bone seen in this study were achieved by treat­
ment with slightly supraphysiological doses of both E2 a nd 
DHT. One cannot exclude that an effect on trabecular bone 
of similar magnitude could be reached by monotherapy 
using even higher doses of E2 or DHT. However, treatment 
with higher doses than used in this study would probably be 
associated with an increased risk of side effects. Therefore, 
we propose that a combined E2 and DHT treatment might, 
in a more specific manner than monotherapy, achieve a 
target trabecular bone mass without the risk of dose-
dependent s ide effects. 
In co ntrast to the effects on trabecular bone seen in t his 
study, no interactive effects of combined E2 and DHT 
treatment were seen on cortical bone parameters. Further­
more, regarding the longitudinal bone growth, DHT coun­
teracted the inhibitory effect of E2 on longitudinal bone 
growth in OVX rats. Longitudinal bone growth is dependent 
on the number of cell divisions of growth plate chondro­
cytes within each column and the height of the terminally 
differentiated hypertrophic chondrocytes. Addition of DHT 
to E2 fully counteracted the E2-induced reduction in the 
height of hypertrophic chondrocytes and partially counter­
acted the inhibitory effect on the number of proliferative 
chondrocytes. Interestingly, the inhibitory effect of E2 and 
the counteracting effect of addition of DHT to E2 on growth 
plate morphology were associated with similar alterations in 
serum levels of IGF-I, suggesting that the growth hormone/ 
IGF-I axis might be involved in the effects on growth plate 
morphology. Such a link is further supported by a previous 
report showing decreased height of hypertrophic chondro­
cytes in IGF-I knockout mice (i.e., a similar effect as 
observed in o ur OVX animals).(36) In a ccordance with our 
results on bone length, Coxam et al.(37) found that DHT 
counteracted the inhibitory effect of E2 on longitudinal bone 
growth. In contrast to our results, they found no effect of E2, 
DHT, or the combined treatment on trabecular bone volume 
as assessed by histomorphometry, and thus a possible ad­
ditive effect of the combined treatment on trabecular bone 
could not be evaluated. Coxam et al. used a comparable 
treatment length (8 weeks) and dose of E2, whereas the 
doses of DHT were approximately double and 8-fold higher. 
However, an important difference between our studies is 
that the treatment was initiated directly after OVX in this 
study, whereas it w as 8 weeks a fter OVX in the study by 
Coxam et al. 
Our results show that combined estrogen and androgen 
treatment might result in an additive effect (trabecular 
bone), no interaction (cortical bone), or an antagonistic 
effect (longitudinal bone growth) depending on the bone 
parameter investigated. 
In conclusion, combined estrogen and androgen treatment 
exerts an additive protective effect on trabecular bone in 
OVX rats. This additive effect on trabecular bone mass 
might be partially explained by AR activation attenuating 
the inhibitory effect of ER activation on bone formation. 
Our findings suggest that a combined t reatment of selective 
ER modulators and selective AR modulators might be ben­
eficial in the treatment of o steoporosis. 
ACKNOWLEDGMENTS 
This study was supported by the Swedish Research Coun­
cil (4250, 12206), the Swedish Foundation for Strategic 
Research, the European Commission Grant QLK4-CT-
2002-0258. the Lundberg Foundation, the Torsten and Rag­
nar Söderberg's Foundation, the Novo Nordisk Foundation, 
the Petrus and Augusta Hedlund's Foundation, the Västra 
Götaland Foundation, the Göteborg Medical Society, the 
Tore Nilson Foundation, and Grant OT/Ol/39 from Re­
search Fund K.U. Leuven. The authors thank Britt-Mari 
Larsson, Maud Petersson, and Anette Hansevi for excellent 
technical support. 
REFERENCES 
1. Orwoll ES 2003 Men. bone and estrogen: Unresolved issues. 
Osteoporos Int 14:93-98. 
2. Riggs BL. Khosla S. Melton LJ III 1998 A unitary model for 
involutional osteoporosis: Estrogen deficiency causes both type I 
and type II osteoporosis in postmenopausal women and contributes 
to bone loss in aging men. J Bone Miner Res 13:763-773. 
3. Vande rsc hue ren D. Vandenput L. Boonen S. Lindberg MK. Bouil­
lon R. Ohlsson C 2004 Androgens and bone. Endocr Rev 25:389-
425. 
4. Riggs BL. Khosla S. Melton LJ III 2(X)2 Sex steroids and the 
construction and conservation of the adult skeleton. Endocr Rev 
23:279 -302. 
5. Nilsson L O, Boman A. Savendahl L. Grigelioniene G. Ohlsson C. 
Ritzen EM. Wroblewski J 1999 Demonstration of estrogen 
receptor-beta immunoreactivity in human growth plate cartilage. 
J C lin Endocrinol Metab 84:370-373. 
6. Arts J, Kuiper GG. Janssen JM. Gustafsson JÅ. Lowik CW. Pols 
HA. van Leeuwen JP 1997 Differential expression of estrogen 
receptors alpha and beta mRNA during differentiation of human 
osteoblast SV-HFO cells. Endocrinology 138:5067-5070. 
7. Onoe Y. Miyaura C. Ohta H. Nozawa S. Suda T 1997 Expression 
of estrogen receptor beta in rat bone. Endocrinology 138:4509-
4512. 
8. Wiren KM 2002 Androgen action in bone. Basic cellular and 
molecular aspects. In: Bliziotes M (ed.) Osteoporosis. Pathophys­
iology and Clinical Management. Humana Press, Totowa. NJ. 
USA, pp. 349-373. 
9. Vidal O. Kindblom LG, Ohlsson C 1999 Expression and localiza­
tion of estrogen receptor-beta in m urine and human bone. J Bone 
Miner Res 14:923-929. 
10. Lindberg MK. Weihua Z. Andersson N, Moverare S. Gao H. Vidal 
O. Erlandsson M. Windahl S. Andersson G. Lubahn DB. Carlsten 
H, Dahlman-Wright K. Gustafsson JÀ. Ohlsson C 2002 Estrogen 
receptor specificity for the effects of estrogen in ovariectomized 
mice. J Endocrinol 174:167-178. 
11. Sims NA, Clement-Lacroix P. Minet D. Fraslon-Vanhulle C, 
Gaillard-Kelly M. Resche-Rigon M. Baron R 2003 A functional 
androgen receptor is not sufficient to allow estradiol to protect 
bone after gonadectomy in estradiol receptor-deficient mice. J Clin 
Invest 111:1319-1327. 
12. Moverare S. Venken K, Eriksson AL, Andersson N, Skrtic S, 
Wergedal J. Mohan S. Salmon P. Bouillon R. Gustafsson JÅ. 
Vanderschueren D. Ohlsson C 2003 Differential effects on bone of 
estrogen receptor alpha and androgen receptor activation in orchi-
dectomized adult male mice. Proc Natl Acad Sei USA 100:13573-
13578. 
13. McDougall KE. Perry MJ. Gibson RL, Colley SM. Korach KS, 
Tobias JH 2003 Estrogen receptor-alpha dependency of estrogen's 
stimulatory action on cancellous bone formation in male mice. 
Endocrinology 144:1994-1999. 
14. Sims NA. Dupont S, Krust A, Clement-Lacroix P. Minet D. 
Resche-Rigon M. Gaillard-Kelly M. Baron R 2002 Deletion of 
estrogen receptors reveals a regulatory role for estrogen receptors-
beta in bone remodeling in females but not in males. Bone 30:18-
25. 
15. Windahl SH. Hollberg K. Vidal O. Gustafsson JÅ. Ohlsson C. 
Andersson G 2001 Female estrogen receptor beta-/- mice are 
ADDITIVE EFFECTS OF ESTROGEN AND ANDROGEN ON BONE 1839 
partially protected against age-related trabecular bone loss. J Bone 
Miner Res 16:1388-1398. 
16. Windahl SH. Vidal O. Andersson G. Gustafsson JÅ. Ohlsson C 
1999 Increased cortical bone mineral content but unchanged tra­
becular bone mineral density in female ERbeta(-/-) mice. J Clin 
Invest 104:895-901. 
17. Lindberg MK. Moverare S. Skrtic S, Gao H. Dahlman-Wright K, 
Gustafsson JÅ. Ohlsson C 2(X)3 Estf ogen receptor (ER)-beta re­
duces ERalpha-regulated gene transcription, supporting a "ying 
yang" relationship between ERalpha and ERbeta in mice. Mol 
Endocrinol 17:203-208. 
18. Vandenput L. Ederveen AG. Erben RG. Stahr K. Swinnen JV. Van 
Herck E. Verstuyf A. Boonen S. Bouillon R. Vanderschueren D 
2(H) 1 Testosterone prevents orchidectomy-induced bone loss in 
estrogen receptor-a knockout mice. Biochem Biophys Res Com­
mun 285:70-76. 
19. Kousteni S. Bellido T. Plotkin LI. O'Brien CA. Bodenner DL. Han 
L. Han K. DiGregorio GB. Katzenellenbogen JA, Katzenellenbo­
gen BS. Roberson PK. Weinstein RS. Jilka RL, Manolagas SC 
2001 Nongenotropic. sex-nonspecific signaling through the estro­
gen or androgen receptors: Dissociation from transcriptional ac­
tivity. Cell 104:719-730. 
20. Kousteni S. Chen JR. Bellido T. Han L. Ali AA. O'Brien CA. 
Plotkin L. Fu Q. Mancino AT. Wen Y. Vertino AM. Powers CC. 
Stewart SA. Ebert R, Parfitt AM. Weinstein RS. Jilka RL. Mano-
lagas SC 2(X)2 Re versal of bone loss in mice by nongenotropic 
signaling of sex steroids. Science 298:843-846. 
21. Kousteni S. Han L. Chen JR. Almeida M. Plotkin LI, Bellido T. 
Manolagas SC 2003 Kinase-mediated regulation of common tran­
scription factors accounts for the bone-protective effects of sex 
steroids. J Clin Invest 111:1651-1664. 
22. Kawano H. Sato T. Yamada T. Matsumoto T. Kawaguchi H. Kato 
S 2(K»2 Both androgen and estrogen signalings contribute to the 
maintenance of bone mass in males: Analyses of male androgen 
receptor deficient mice. J Bone Miner Res 17:S1:S365. 
23. Vandenput L. Boonen S. Erben RG. Van Herck E. Swinnen JV. 
Bouillon R. Vanderschueren D 2002 Anabolic effects of testoster­
one on bone require the presence of a functional androgen receptor 
in male mice. J Bone Miner Res 17:S1;S290. 
24. Lindberg MK. Moverare S. Skrtic S. Alatalo S. Halleen J. Mohan 
S. Gustafsson JÅ. Ohlsson C 2002 Two different pathways for the 
maintenance of t rabecular bone in adult male mice. J Bone Miner 
Res 17:555-562. 
25. Vandenput L. Boonen S. Van Herck E. Swinnen JV, Bouillon R. 
Vanderschueren D 2002 Evidence from the aged orchidectomized 
male rat model that l7beta-estradiol is a more effective bone-
sparing and anabolic agent than 5alpha-dihydrotestosterone. 
J Bone Miner Res 17:2080-2086. 
26. Vidal O. Lindberg MK. Hollberg K. Baylink DJ. Andersson G. 
Lubahn DB. Mohan S. Gustafsson JÅ. Ohlsson C 2(XX) Estrogen 
receptor specificity in th e r egulation of skeletal growth and matu­
ration in m ale mice. Proc Natl Acad Sei USA 97:5474-547*) 
27. Feldkamp LA. Davis LC. Kress JW 1984 Practical cone-beam 
algorithm. J Opt Soc Am A Opt Image Sei Vis 1:612-619. 
28. Waarsing JH. Day JS. Weinans H 2004 An improved segmentation 
method for in vivo micro-CT imaging. J Bone Miner Res (in 
press). 
29. Hildebrand T. Ruegsegger P 1997 Quantification of bone micro­
architecture with the structure model index. Comput Methods 
Biomech Biomed Engin 1:15-23. 
30. Chagin AS. Lindberg MK. Andersson N. Moverare S. Gustafsson 
JA. Savendahl L. Ohlsson C 2004 Estrogen receptor-beta inhibits 
skeletal growth and has the capacity to mediate growth plate fusion 
in f emale mice. J Bone Miner Res 19:72-77. 
31. Riggs BL. Wahner HW. Dunn WL. Mazess RB. Offord KP. 
Melton LJ III 1981 Differential changes in bone mineral density of 
the appendicular and axial skeleton with aging: Relationship to 
spinal osteoporosis. J C lin Invest 67:328-335. 
32. Manolagas SC 2000 Birth and death of bone cells: Basic regulatory 
mechanisms and implications for the pathogenesis and treatment of 
osteoporosis. Endocr Rev 21:115-137. 
33. Vanderschueren D. Van Herck E. Nijs J. Ederveen AG. De Coster 
R. Bouillon R 1997 Aromatase inhibition impairs skeletal model­
ing and decreases bone mineral density in growing male rats. 
Endocrinology 138:2301-2307. 
34. Buchanan JR. Hospodar P. Myers C. Leuenberger P. Demers LM 
1988 Effect o f excess endogenous androgens on bone density in 
young women. J C lin Endocrinol Metab 67:937-943. 
35. Raisz LG. Wiita B. Artis A. Bowen A. Schwartz S. Trahiotis M. 
Shoukri K. Smith J 1996 Comparison of the effects of estrogen 
alone and estrogen plus androgen on biochemical markers of bone 
formation and resorption in p ostmenopausal w omen. J Clin Endo­
crinol Metab 81:37-43. 
36. Wang J. Zhou J. Bondy CA 1999 Igfl promotes longitudinal bone 
growth by insulin-like actions augmenting chondrocyte hypertro­
phy. FASEB J 13:1985-1990. 
37. Coxam V. Bowman BM. Mecham M. Roth CM. Miller MA. Miller 
SC 1996 Effects of dihydrotestosterone alone and combined with 
estrogen on bone mineral density, bone growth, and formation 
rates in o variectomized rats. Bone 19:107-114. 
Address reprint requests to: 
Claes Ohlsson, MD, PhD 
Division of Endocrinology 
Department of Internal Medicine 
Gröna Stråket 8 
Göteborg S-413 45, Sweden 
E-mail: claes. ohlsson @medic.gu. se 
Received in original form May 5, 2004; in revised form June 9, 
2004: accepted July 2. 2004. 

IV 

0888-8809/03/$ 15.00/0 
Printed in U.S.A. 
Molecular Endocrinology 17(2):203-208 
Copyright © 2003 by The Endocrine Society 
doi: 10.121Q/me.2002-0206 
Estrogen Receptor (ER)-ß Reduces ERa-Regulated 
Gene Transcription, Supporting a "Ying Yang" 
Relationship between ER« and ERß in Mice 
MARIE K. LINDBERG, SOFIA MOVÉRARE, STANKO SKRTIC, HUI GAO, 
KARIN DAHLMAN-WRIGHT, JAN-ÅKE GUSTAFSSON, AND CLAES OHLSSON 
Division of Endocrinology (M.K.L., S.M., S.S., C.O.), Department of Internal Medicine, Sahlgrenska 
University Hospital, S-41345 Gothenburg, Sweden; and Department of Medical Nutrition and 
Department of Biosciences (J.-Å.G., H.G., K.D.-W.), Karolinska Institute, Novum, S-14157 Huddinge, 
Sweden 
Estrogen is of importance for the regulation of 
adult bone metabolism. The aim of the present 
study was to determine the role of estrogen recep-
tor-ß (ERß) in vivo on global estrogen-regulated 
transcriptional activity in bone. The effect of estro­
gen in bone of ovariectomized mice was deter­
mined using microarray analysis including 9400 
genes. Most of the genes (95% = 240 genes) that 
were increased by estrogen in wild-type (WT) 
mice were also increased by estrogen in ERß-
inactivated mice. Interestingly, the average stimu­
latory effect of estrogen on the mRNA levels of 
these genes was 85% higher in ERß-inactivated 
than in WT mice, demonstrating that ERß reduces 
estrogen receptor-« (ERa)-regulated gene tran­
scription in bone. The average stimulatory effect of 
estrogen on estrogen-regulated bone genes in 
ERa-inactivated mice was intermediate between 
that seen in WT and ERaß double-inactivated mice. 
Thus, ERß inhibits ERa-mediated gene transcrip­
tion in the presence of ERa, whereas, in the ab­
sence of ERa, it can partially replace ERa. In con­
clusion, our in vivo data indicate that an important 
physiological role of ERß is to modulate ERa-
mediated gene transcription supporting a "Ying 
Yang" relationship between ER« and ERß in mice. 
(Molecular Endocrinology 17: 203-208, 2003) 
ESTROGEN is OF importance for the regulation of adult bone metabolism. We and others have pre­
viously demonstrated that female estrogen receptor-ß 
(ERß)-inactivated or ERa+/+ß~'~ mice (BERKO) have 
an increased amount of cortical bone and are partly 
protected against age-related trabecular bone loss 
that normally occurs in old female wild-type (WT) mice. 
Therefore, one may speculate that ERß represses the 
bone-protective effect of estrogen mediated via estro­
gen receptor-a (ERa) (1-3). A possible interaction be­
tween ERa and ERß in the regulation of transcriptional 
activity has previously been investigated in different in 
vitro systems. It is clear that ERß and ERa can form 
heterodimeric complexes with retained DNA-binding 
ability (4). Transient transfection assays have demon­
strated that ERß has the capacity to repress the tran­
scriptional activity of ERa (5, 6). Furthermore, when 
complexed with estradiol, ERa and ERß signal in op­
posite directions from an activator protein 1 site (7). An 
inhibitory effect of ERß might be explained by the 
finding that ERß does not contain a strong activation 
function 1 within its amino terminus but, rather, con­
tains a repressor domain; when this particular seg­
ment is removed, the overall transcriptional activity of 
Abbreviations: BERKO, ERa+/+/r'~; DERKO, ERa ' ß ' ; 
ER, estrogen receptor: ERKO, ERa ß ' i EST, expressed 
sequence tag; GR, glucocorticoid receptor; ovx, ovariecto­
mized; PR, progesterone receptor; WT, wild-type. 
the receptor increases (6). Thus, previous in vitro data 
indicate that ERß can sometimes act as a dominant 
negative regulator of ERa activity. Gene expression 
profiling opens up possibilities to investigate the inter­
play between ERa and ERß in a global sense. The aim 
of the present study was to determine, in vivo, the role 
of ERß and its possible interactions with ERa in global 
estrogen-regulated transcriptional activity in bone. 
RESULTS AND DISCUSSION 
ERß Reduces ERa-Regulated Gene Transcription 
in Bone and Liver 
The effects of estrogen on global gene expression in 
humerus from ovariectomized (ovx) mice were deter­
mined by microarray analysis. Most of the genes 
(95%, 240 genes) that were increased by estrogen in 
WT mice were also increased by estrogen in BERKO 
mice, indicating that ERß, in the presence of ERa, is 
generally not required for estrogen-regulated gene 
transcription in bone. The relative magnitude of the 
effect of estrogen in WT and BERKO mice was com­
pared for these genes. Interestingly, the average stim­
ulatory effect of estrogen on the expression of these 
genes was 85% higher in BERKO than in WT mice 
and, when considering the individual genes, it was 
found that 80% of the genes were more regulated by 
203 
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estrogen in BERKO than in WT mice (Fig. 1A and Table 
1). ER« mRNA levels in bone were unchanged in 
3-month-old estrogen-treated female BERKO mice 
compared with WT mice (WT, 100 ± 13%, BERKO, 
132 ± 29% of WT mice, n = 7-8) as determined by 
real-time PCR. 
To study whether the effect of ERß to reduce estro­
gen-stimulated gene transcription was specific for 
bone or whether it could be found in other tissues as 
well, the effect of estrogen on estrogen-regulated 
genes was analyzed in the liver. In accordance with the 
results from the humerus, the average stimulatory ef­
fect of estrogen in liver was increased in BERKO com­
pared with WT mice (184% of WT) and when the 
individual genes were considered it was found that 
76% of the genes were more regulated by estrogen in 
BERKO than in WT mice (Fig. 1B and Table 1). As a 
negative control, we compared the expression of all 
genes not regulated by estrogen (n = 9060) without 
finding any difference between WT and BERKO mice 
(data not shown). The stimulatory effect of estrogen on 
the expression of 13 genes in bone and 8 genes in liver 
was confirmed by real-time PCR analysis (Fig. 2 and 
data not shown). Thus, in the presence of ERa, it is 
clear that ERß reduces the global estrogen-stimulated 
gene transcription in bone and liver. This is the first 
demonstration that ERß is a global inhibitor of ER«-
regulated gene transcription in mice. In contrast, a 
minority of the estrogen-regulated genes were more 
regulated in WT than in BERKO mice, which might 
indicate that ERß has an additional role as a potent 
activator of a small specific gene set. However, we 
believe, rather, that these results represent a random 
distribution of several estrogen-regulated genes, 
where most genes are more regulated and very few 
are less regulated in BERKO than in WT mice. 
A. Stimulatory Effect of Estrogen in Bone B. Stimulatory Effect of Estrogen in Liver 
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Fig. 1. ER/3 Reduces ERa-Regulated Gene Transcription in Bone and Liver 
Stimulatory (A and B) and inhibitory (C and D) effects of estrogen on estrogen-regulated gene transcription in bone (A and C) 
and liver (B and D) of ovx WT and BERKO mice as measured using microarray analysis. The percent increase over vehicle (A and 
B) or decrease below vehicle (C and D) for each individual estrogen-regulated gene is given for WT (x-axis) and BERKO (y-axis) 
mice. The black line indicates the theoretical position of genes regulated by estrogen to the same magnitude in WT and BERKO 
mice. 
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A global ERn-repressing effect of ERß on transcrip­
tional activity is supported by recent functional in vivo 
studies demonstrating that ERß represses some ERa-
mediated effects, including effects on female bone, 
thymus involution, fat reduction, and proliferative ef­
fects in uterus and prostate (8, 9). 
The number of genes inhibited by estrogen in bone 
from both WT and BERKO mice was lower than the 
number of genes stimulated by estrogen (stimulated, 
240; inhibited, 35). The average inhibitory effect of 
Table 1. Effect of Estrogen in WT and BERKO Mice 
WT (%) BERKO (%) 
Stimulation in bone 275 ± 14 511 ± 30* 
(n = 240) 
Stimulation in liver 472 ± 67 868 ± 179b 
(n = 34) 
Inhibition in bone -59 ± 1 -66 ± 2a 
(n = 35) 
Inhibition in liver - 60 ± 3 -65 ± 41 
(n = 6) 
Effect of estrogen on estrogen-regulated gene transcription 
in bone and liver of ovx mice as studied by microarray anal­
ysis. Values are the average effect of estrogen expressed as 
percent stimulation above or inhibition below vehicle and are 
given as mean ± SEM. n = number of genes regulated by 
estrogen in both WT and BERKO mice. 
a P < 0.001 BERKO vs. WT, Student's paired t test. 
b P < 0.05 BERKO vs. WT, Student's paired t test. 
estrogen on these genes was more pronounced in 
BERKO compared with WT mice and, when consider­
ing the individual genes, it was found that 83% of the 
genes were more regulated by estrogen in BERKO 
than in WT mice (Fig. 1C and Table 1). The number of 
genes inhibited by estrogen in liver (n = 6) was too low 
to permit any statistical difference between WT and 
BERKO mice even though a similar tendency as in 
bone was found (Fig. 1D and Table 1). These data 
indicate that ERß, in the presence of ER«, not only 
reduces the stimulatory but also the inhibitory effect of 
estrogen on gene transcription. 
ER/3 Can Partially Replace ERa in Estrogen-
Regulated Gene Transcription 
The function of ERß on estrogen-regulated gene 
transcription in the absence of ERa was investigated 
by comparing the effect of estrogen in bone from ovx 
WT, ER«-'-ß+/" (ERKO), BERKO, and ERcr'-ß"'" 
(DERKO) mice. We could, by microarray analysis, 
clearly demonstrate that more than 98% of the genes 
stimulated by estrogen in WT and BERKO mice were 
unchanged by estrogen in DERKO mice, demonstrat­
ing that, for most genes, either ERa or ERß is required 
for the mediation of the effect of estrogen (Fig. 3). Less 
than 2% of the estrogen-regulated genes were regu­
lated by estrogen also in DERKO mice, indicating that 
these few genes were regulated in an ERa/ERß-
1800 
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• estrogen 
** ** 
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•S 1000 
800 
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** 
200 
#32 #34 #36 #200 #29 #30 
humerus liver  
Fig. 2. TaqMan Verification of DNA Microarray Analysis 
Verification of DNA microarray analysis with relation to the stimulatory effect of estrogen on three different genes in bone (gene 
34, 36, and 200 according to the supplemental data file) and three other genes in liver (gene 29, 30, and 32 according to the 
supplemental data file) as measured by real-time PCR on individual mice. Values are shown as percent of vehicle-treated WT ± 
SEM. Student's t test. **, P < 0.01, estrogen vs. vehicle. 
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Fig. 3. ERß Can Partially Replace ERa in Estrogen-
Regulated Gene Transcription 
Stimulatory effects of estrogen on estrogen-regulated 
gene transcription in bone of ovx WT, ERKO, BERKO, and 
DERKO mice as measured using microarray analysis. The 
percent increase over vehicle for each individual estrogen-
regulated gene (n = 240) is given. 
independent manner, but one cannot exclude a minor 
ERa activity remaining in these mice (10, 11). Alterna­
tively, estrogen has been suggested to exert non-
genomic actions via cell membrane receptors in a 
variety of cell types (12-14), and the effect might also 
be due to some low-affinity binding to other known 
nuclear receptors (14). Interestingly, the average stim­
ulatory effect of estrogen in ERKO (176 ± 11 % over 
vehicle) was intermediate between that seen in WT 
(275 ± 14% over vehicle) and DERKO (-7 ± 3% over 
vehicle) mice (Fig. 3). 
Furthermore, the effects of estrogen in humerus of 
ovx WT, ERKO, BERKO, and DERKO mice were in­
vestigated by a statistical model using three-way 
ANOVA (gene, n = 240; ERa + or -, ERß + or -) with 
gene as block effect, demonstrating that all these four 
groups are significantly different from each other (P < 
0.00001). Similar results were also seen using three-
way ANOVA applied on ranks within blocks, with gene 
as block effect (P < 0.00001). These data demonstrate 
that ERß, in the absence of ERa, is able to partially 
mediate the effect of estrogen on gene transcription 
(Fig. 3). However, ERa is more efficient than ERß in 
mediating the effect of estrogen on gene transcription. 
These analyses also demonstrated that there is a clear 
negative interaction between the effect of ERa and 
ERß, which could be interpreted as meaning that ERß 
significantly reduces the stimulatory effect of ERa 
(Figs. 3 and 4). Thus, ERß inhibits ERa-mediated gene 
m E 160 
S — (00 
Inhibitory effect of ERß 
in the presence of ERa 
Stimulatory effect of ERß 
in the absence of ERa 
Fig. 4. ERß inhibits ERa-Mediated Gene Transcription in the 
Presence of ERa, Whereas It Can Partially Replace ERa in the 
Absence of ERa 
The figure is based on the effects of estrogen in bone of 
ovx WT, ERKO, BERKO, and DERKO mice. These effects 
were investigated by a statistical model using three-way 
ANOVA (gene, n = 240; ERa + or - , ERß + or -) with gene 
as block effect, demonstrating that all four groups are signif­
icantly different from each other (P < 0.00001). The average 
stimulatory effect of estrogen on the 240 estrogen-regulated 
genes is given and expressed as percent of WT. 
transcription in the presence of ERa, whereas it can 
partially replace ERa in the absence of ERa (Fig. 4). 
It has previously been shown, both for the two pro­
gesterone receptor (PR) s ubtypes (PR-A and PR-B), 
and for the two glucocorticoid receptor (GR) subtypes 
(GRo and GRß), that one of these two subtypes can 
act as a dominant negative inhibitor of the transcrip­
tional activity of the other subtype [PR-A inhibits PR-B 
and GRß inhibits GRa (15-17)]. Our present in vivo 
study together with previous in vitro studies suggest 
that ERa and ERß provide yet another example of two 
nuclear receptor subtypes that demonstrate distinct 
transcriptional activities. The contrasting transcrip­
tional activities of the different subtypes of PR, GR, 
and ER indicate that the relative tissue distributions of 
receptor subtypes are a major determinant of the bi­
ological effects of their respective ligands. 
The increased estrogen-regulated gene transcrip­
tion in BERKO mice compared with WT mice might be 
explained by the fact that ERß is a transdominant 
repressor of ERa. An alternative, and more probable, 
explanation is a competition between two activators, 
ERa and ERß, which exhibit different intrinsic activi­
ties. A competition between the more active ERa and 
the less active ERß in WT mice results in a reduced 
gene activation compared with the situation in BERKO 
mice where only the more active ERa is present. The 
interesting finding that ERß can reduce the transcrip­
tional activity of ERa in vivo was, in the present study, 
obtained from two tissues, liver and bone, which both 
seem to be mainly ERa controlled. In other tissues, 
including prostate, lung, and ovary, it is clear that ERß 
is a major regulator in its own right (8, 9, 18). Accord­
ingly, we cannot extrapolate the present data to con­
clude, in general, that repression of ERa is the major 
physiological function of ERß in all tissues. 
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In the present study, mice were treated for 3 wk with 
estradiol. Therefore, it is not clear which genes were 
directly transcriptionally regulated by estradiol and 
which genes were secondarily regulated by other 
genes regulated by estradiol. Furthermore, the mi-
croarray data do not distinguish between changes in 
transcription vs. changes in RNA processing or RNA 
stability. Thus, the present result should be interpreted 
as the net result of estrogen on mRNA levels after 
chronic estradiol treatment. 
In conclusion, our data indicate that an important 
role of ER/3 is to modulate ERa-mediated gene tran­
scription in bone and liver, supporting a "Ying Yang" 
relationship between ER« and ER/3 in mice. 
MATERIALS AND METHODS 
Animals 
ER-inactivated mice were bred as previously described (19). 
Male double-heterozygous (ERa1 ' ß"~) mice were mated 
with female double-heterozygous (ERa ' ' ß ' ' ) mice, result­
ing in ERa+/+ß+/4 (WT), ERa 7 /3'" (ERKO), ERa^'ß ' 
(BERKO), and ERa ' ß ' (DERKO) offspring (20-22). The 
diet, housing, and genetic background were as previously 
described (22). The mice were ovx at 2 months of age. Ova­
ries were removed after a flank incision and the incisions were 
closed with metallic clips. After recovery for 4 d, mice were 
injected sc with 2.3 ^g/mouse/d of 17/3-estradiol benzoate 
(Sigma, St. Louis, MO) for 5 d/wk during a 3-wk period. 
Control mice received injections of vehicle oil (olive oil, Apo­
teksbolaget, Gothenburg, Sweden). The study protocol was 
reviewed and approved by the ethical committee at the Uni­
versity of Gothenburg. 
DNA Microarray Analysis 
RNA from humerus (n = 6: WT vehicle, DERKO estrogen; n = 
7: WT estrogen; n = 8: BERKO vehicle, BERKO estrogen; n = 
4: DERKO vehicle; n = 3: ERKO vehicle, ERKO estrogen) and 
liver (n - 6: WT vehicle, WT estrogen, BERKO vehicle, 
BERKO estrogen, DERKO vehicle and DERKO estrogen; n = 
4: ERKO vehicle, ERKO estrogen) were prepared as de­
scribed elsewhere (23). The RNA was further purified using 
RNeasy Kit (QIAGEN, Chatsworth, CA). For microarray as­
says the RNA samples were divided into two pools per animal 
group, whereas for the confirmatory real-time PCR analysis 
each individual animal was analyzed separately. The pooled 
RNA was reverse transcribed into cDNA, labeled, and ana­
lyzed by DNA microarray (MG-U74A Array; Affymetrix, Santa 
Clara, CA). The array represents approximately 5700 charac­
terized mouse genes and approximately 3700 uncharacter-
ized expressed sequence tags (ESTs) (in t otal, 9400). In the 
present article we do not distinguish between characterized 
mouse genes and uncharacterized ESTs. Preparation of 
labeled cRNA and hybridization was done according to the 
Affymetrix Gene Chip Expression Analysis manual. 
Bioinformatics 
Scanned output files were analyzed using Affymetrix Micro 
Array Suite Version 4.0.1 software. To allow comparison of 
gene expression, both between groups and between tissues, 
the GeneChips were globally scaled to an average intensity of 
500. The estrogen-regulated genes were determined by cal­
culating the fold change in average between vehicle-treated 
and estrogen-treated samples. Comparisons were made be­
tween the two vehicle-treated and the two estrogen-treated 
GeneChips, generating a total of four comparisons. We de­
fined very strict criteria for genes to be regarded as regulated; 
1) the absolute call for the gene had to be present (i.e. 
regarded by the software to be expressed at a detectable 
level; Affymetrix Micro Array Suite Version 4.0.1) for all 
GeneChips; 2) at least three of the four comparisons had to 
be considered increased (I) or decreased (D) according to 
Affymetrix algorithms; 3) the average fold increase or de­
crease of the four comparisons should be at least 2.0-fold. 
Thus, we may have excluded some estrogen-regulated 
genes but this was done to avoid false positives among the 
regulated genes. The average coefficient of variation for 
the four microarray comparisons was 22.8% for the 240 
estrogen-regulated genes in bone. 
For determination of the ER specificity of the genes regu­
lated by estrogen in WT mice, the same rules as above were 
applied for comparisons between vehicle and estrogen-
treated ERKO, BERKO, and DERKO GeneChips. 
Real-Time PCR Analysis 
The confirmatory real-time PCR analyses were, as described 
in the microarray section, run on each individual sample. The 
analyses were performed using the ABI Prism 7700 Se­
quence Detection System (PE Applied Biosystems, Stock­
holm, Sweden) using probes labeled with the reporter fluo­
rescent dye FAM. Predesigned primers and a probe labeled 
with the reporter fluorescent dye VIC, specific for 18S rRNA, 
were included in the reactions as an internal standard. The 
oligonucleotide primers and probes were purchased from PE 
Applied Biosystems. The cDNA was amplified at the following 
conditions: 1 cycle at 50 C for 2 min and 95 C for 10 min, 
followed by 40 cycles at 95 C for 15 sec and 60 C for 1 min. 
The mRNA amount of each gene was calculated using the 
Standard Curve Method (multiplex reaction, following the 
instructions in User Bulletin no. 2, PE Applied Biosystems) 
and adjusted for the expression of 18S rRNA. 
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ABSTRACT 
It was recently reported that the synthetic compound estren 
increases bone mass without affecting reproductive organs or 
classic transcription. The aim of the present study was to 
further characterize the in vivo and in vitro effects of estren. We 
demonstrate that estren is a selective estrogen receptor mod­
ulator (SERM) with a strong effect on thymus, a moderate effect 
on uterus and trabecular bone, but no major effect on fat or 
cortical bone in 11 -month-old ovariectomized mice. The effect 
of estren on trabecular bone and uterus is mediated via estro­
gen receptors (ERs) because no effect is seen in ER double-
inactivated mice. Furthermore, with the use of ERa- and ERß-
expressing reporter cell lines, we demonstrate that estren 
displays an agonistic effect on transcriptional activity of an estro­
gen-responsive element-driven reporter gene with a degree of 
agonism similar to that of 170-estradiol for both ERa and ERß. 
Thus, estren has the capacity to exert genomic effects via both 
ERa and ERß. We conclude, in contrast to what was previously 
reported by others, that estren is a SERM with transcriptional 
activity. 
Estrogens and androgens are of importance for the regu­
lation of bone metabolism in both males and females. Skele­
tal effects of sex steroids are mediated via estrogen receptors 
(ERs) and the androgen receptor (AR), which are nuclear 
receptors with transcriptional activity. However, a variety of 
cell types respond rapidly to estrogens within seconds or 
minutes, making a classic genomic mechanism of action un­
likely (Wehling, 1997; Brubaker and Gay, 1999; McEwen and 
Alves, 1999; Compston, 2001), and there are now several 
pieces of evidence supporting the notion of nongenomic func­
tions of sex-steroid receptors (Endoh et al., 1997; Brubaker 
and Gay, 1999; Migliaccio et al., 2000; Simoncini et al., 2000; 
Compston, 2001; Duan et al., 2001; Kousteni et al., 2001). 
Furthermore, Kousteni et al. (2001) proposed that ERa, ERß, 
or AR could transmit nongenomic antiapoptotic effects on 
osteoblasts in vitro with similar efficiency, irrespective of 
whether the ligand is an estrogen or an androgen. It has been 
suggested that the genomic mechanisms mediate the repro-
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ductive effects, whereas the nongenomic effects are respon­
sible for the bone-sparing effect of estrogens (Kousteni et al., 
2001, 2002). The synthetic compound 4-estren-3a,17ß-diol 
(estren) has recently been described to increase bone mass 
without affecting reproductive organs or classic transcription 
(Kousteni et al., 2001, 2002). The statement of an absence of 
transcriptional activity for estren is derived from an in vitro 
experiment in which estren did not induce C3 transcription 
in ERa-transfected HeLa cells (Kousteni et al., 2001, 2002). 
The aims of the present study were the following: 1) to 
determine the tissue specificity for the effect of estren; 2) to 
determine whether the in vivo effect of estren is mediated via 
ERs and/or AR with the same efficiency; and 3) to determine 
in vitro, using ER-expressing reporter cell lines, whether 
estren has any transcriptional activity. We demonstrate here 
that estren is a selective estrogen receptor modulator 
(SERM) with transcriptional activity. 
Materials and Methods 
Animals. Male and female double-heterozygous (ERa+/_ß+/~) 
mice were mated, resulting in WT, ERa_/_ERß+/+ (ERaT/-), ERa+/ 
+ERß_/~ (ERß-/_) and ERa_/_ERß_/~ (ERa~/_ß-/~) offspring with 
a mixed C57BL/6J/129 background (Lubahn et al., 1993; Krege et al., 
ABBREVIATIONS: ER, estrogen receptor; ERa, estrogen receptor a; ERß, estrogen receptor ß; SERM, selective estrogen receptor modulator; AR, 
androgen receptor; BMD, bone mineral density; BMC, bone mineral content; ovx, ovariectomized; WT, wild type; pQCT, peripheral quantitative 
computerized tomography; FCS, fetal calf serum; ALP, alkaline phosphatase; 293/hERa, human 293 kidney cells expressing estrogen receptor a; 
293^ERß, human 293 kidney cells expressing estrogen receptor ß; ICI 182,780, fulvestrant. 
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1998). Genotyping of tail DNA was performed at 3 weeks of age as 
described previously (Vidal et al., 2000). Animals had free access to 
fresh water and soy-free food pellets (R70; Lactamin AB, Stockholm, 
Sweden). At 11 months of age, mice were ovariectomized (ovx) and 
injected daily subcutaneously with 17ß-estradiol benzoate (0.7 /xg/ 
mouse) (Sigma Chemical, St. Louis, MO) or estren (75 /xg/mouse) 
(Steraloids, Newport, RI) for 4 weeks. Control mice received injec­
tions of vehicle oil (olive oil; Apoteksbolaget, Göteborg, Sweden). 
Peripheral Quantitative Computerized Tomography. Com­
puterized tomography was performed with the Stratec peripheral 
quantitative computerized tomography (pQCT) XCT Research M 
(version 5.4B; Norland Corporation, Fort Atkinson, WI) as described 
previously (Windahl et al., 1999). Trabecular bone mineral density 
(BMD) was determined ex vivo, with a metaphyseal pQCT scan of the 
proximal tibia and defined as the inner 45% of the total cross-
sectional area. Cortical bone parameters were determined ex vivo 
with a mid-diaphyseal pQCT scan of the femur. 
Generation of Stable ERa and ER/3 Reporter Cell Lines. 
Generation of stable human embryonic kidney 293 cells (American 
Type Culture Collection no. CRL 1573) expressing human ERa and 
human ERß and the pAERE2-ALP reporter vector has been de­
scribed previously (Barkhem et al., 1998). All cell lines were cultured 
routinely at 37°C in humidified chambers at 5% C02 in minimal 
essential medium (phenol red-free) supplemented with 10% FCS and 
2 mM L-glutamine. 
Assay Procedure for Hormonal Effects on 293/hERa and 
293/hERß Reporter Cells. Cells (25 X 10 3 per well) were seeded 
onto 96-well culture plates in 100 /xl of Coon's/F12 (phenol red-free) 
supplemented with 10% FCS (stripped twice using dextran-coated 
charcoal) and 2 mM L-glutamine. Twenty-four hours later, condi­
tioned medium was replaced with 100 /xl Coon 's/F12 supplemented 
with 1% FCS (stripped twice using dextran-coated charcoal), 2 mM 
L-glutamine, gentamicin (50 /xg/ml), a nd hormonal substances as 
indicated in the figure legends. In all experiments, cells were ex­
posed to hormones for 72 h before harvest and analysis for effect on 
reporter-gene expression. Triplicate determinations of reporter pro­
tein levels in the conditioned media for each concentration of com­
pound were performed in all experiments. 
Assay for Human Placental Alkaline Phosphatase. The level 
of alkaline phosphatase (ALP) expressed from the AERE2-ALP re­
porter vector in the stably transformed 293/hERa and 293/hERß 
reporter cells was determined using a chemiluminescent assay as 
follows: a 10-/xl aliquot of heat-treated (at 65°C for 30 min) condi­
tioned cell-culture medium was mixed with 200 /xl of assay buffer (10 
mM diethanolamine, pH 10.0, 1 mM MgCl2, and 0.5 mM CSPD) in 
white microtiter plates (Dynatech Labs, Chantilly, VA) and incu­
bated at 37°C for 20 min before being transferred to a microplate-
format luminescence counter ( 1450 Microbeta; PerkinElmer Wallac, 
Turku, Finland). The setting of the Microbeta was for a 1-s reading 
of each well. The ALP activity is expressed in luminescence counts 
per second, which is directly proportional to the level of ALP ex­
pressed from the cells. 
Results 
Tissue Specificity for the Effect of Estren Compared 
with the Effect of 17/3-Estradiol. To determine the tissue 
specificity for the effect of estren compared with the effect of 
17ß-estradiol, ovx mice were treated with vehicle, estren, or 
17ß-estradiol (0.7 /xg/mouse/day). Surprisingly, already at an 
estren dose of 75 /xg/mouse/day, a clear effect was seen on the 
uterine weight (132 ± 28% over vehicle), which is in contrast 
to a previous study using a 70% higher dose of es tren and 
demonstrating no uterine effect (Kousteni et al., 2002). The 
effects of estren on different estrogen-responsive tissues were 
then compared with the effects of a physiological dose of 
17ß-estradiol (Lindberg et al., 2002). Both estren and 17ß-
estradiol increased the uterine weight compared with vehicle 
in ovx mice (Fig. 1). The effect of estren on the uterine weight 
was 16% of the effect exerted by 17ß-estradiol (Table 1). As 
expected, the weights of the gonadal and the retroperitoneal 
fat deposits were reduced by 17ß-estradiol in ovx mice. In 
contrast, no effect on these fat deposits was seen by estren 
treatment (Fig. 2). It is well known that estrogen treatment 
decreases the weight of thymus (Marotti et al., 1984). Both 
17ß-estradiol and estren treatment decreased the thymus 
weight, and for this parameter, the effects of estren and 
17ß-estradiol were of the same magnitude (17ß-estradiol, 
-59 ± 11%; estren, — 42 ± 6% compared with vehicle) (Table 
1). Both estren and 17ß-estradiol increased the trabecular 
BMD, and the effect of estren on trabecular BMD was 22% of 
the effect exerted by 17ß-estradiol (Fig. 3A and Table 1). In 
contrast, cortical bone parameters, including cortical bone 
mineral content (BMC), cortical cross-sectional area, and 
cortical thickness, were increased by 17ß-estradiol but not by 
estren (Fig. 3B, Table 1, and data not shown). 
The Effects of Estren Are Mediated Via Estrogen 
Receptors. Because previous in vitro data have indicated 
that the effect of estren is mediated via ERs or the AR with 
similar efficiency (Kousteni et al., 2001, 2002), we designed 
an experiment to determine whether the in vivo effects of 
estren can be mediated via both the ERs and the AR. The in 
vivo effects of estren and 17ß-estradiol were investigated in 
WT and ERoc~/~ ß~/~~ mice. The regulatory effects of estren 
and 17ß-estradiol on uterus, fat, trabecular bone, and cortical 
bone, observed in WT mice, were lost in ERtt~/-ß_/~ mice 
(Figs. 1-3). Thus, the in vivo effects of estren and 17ß-estra-
diol on uterus weight and trabecular bone are mediated via 
ERs, and the AR cannot replace the ERs for the mediation of 
these effects (Figs. 1-3). 
Estren has Transcriptional Activity. The in vivo exper­
iments demonstrated that the effects of estren are mediated 
via ERs. To determine whether estren has any transcrip­
tional activity mediated via ERs, the effect of estren on the 
activation of an estrogen-responsive element-driven reporter 
gene (ALP) was tested in vitro in human 293 kidney epithe-
200 
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B 17ß-estradiol 
• estren 
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Fig. 1. Weight of uterus. Eleven-month-old female WT and ERa ' ß '' 
mice were ovariectomized and then treated with vehicle, 17ß-estradiol 
(0.7 /xg/mouse/day), or estren (75 /ig/mouse/day) for 4 weeks (n = 7-8). 
Values given are means ± S.E .M. +*, p < 0.01, *+*, p < 0.001 versus 
vehicle, Student's t test followed by post hoc analysis according to Bon-
ferroni test. 
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liai ERa (293/hERa)- and ERß (293/hERß)-expressing re­
porter cell lines (Barkhem et al., 1998). The responses of 
293/hERa and 293/hERß to estren are shown in Fig. 4, A and 
B, and expressed as the percentage of agonism of 17/3-estra-
diol. Estren displayed a full agonistic effect on transcrip­
tional activity with a degree of agonism similar to that of 
17ß-estradiol for both receptors (99% agonistic activity via 
ERa and 87% agonistic activity via ERß compared with the 
activity of 17ß-estradiol) (Fig. 4, A and B). As expected from 
previous ER« and ERß binding studies (Kousteni et al., 
2002), the transcriptional potency of estren was lower than 
that of 17ß-estradiol in both the 293/hERa and the 293/hERß 
cell lines (Fig. 4, A a nd B). The ER antagonist ICI 182,780 
antagonized, in a dose-dependent manner, the effect of estren 
in both the 293/hERa and the 293/hERß cells. The potency of 
ICI 182,780 in antagonizing estren-induced gene expression 
was similar in both reporter cell lines (IC50 values: 0.75 nM 
for ERa and 0.57 nM for ERß) (Fig. 4, C and D). Thus, estren 
is a full agonist for the transcriptional activity mediated via 
both ERa and ERß. 
Discussion 
Estrogen replacement therapy is beneficial for the treat­
ment of postmenopausal bone loss but is reported to have 
undesirable effects on reproductive tissue and is associated 
with an increased risk of breast cancer (Riggs and Hart­
mann, 2003). SERMs having the beneficial effects of estrogen 
in bone with reduced side effects in breast and uterus have 
been developed. However, currently available SERMs are 
less potent in bone than estrogen replacement therapy (Del-
mas et al., 1997). Therefore, the recent description of estren 
as a potent stimulator of bone mass and strength without any 
side effects on reproductive organs has been very much ap­
preciated (Kousteni et al., 2001, 2002). Furthermore, the 
described mode of action for the bone-sparing effect of estren 
is unique because it was reported to be a nongenomic effect 
involving functional and direct interactions with components 
of the Src/Shc/extracellular signal-regulated kinase signaling 
pathways. Extranuclear signaling by classic ERs and AR is 
supported by numerous reports describing interactions be­
tween sex-steroid receptors and components of the intracel­
lular signaling machinery including phosphatidylinositol-3-
phosphate kinase, Src, and She (Migliaccio et al., 2000; 
Simoncini et al., 2000; Duan et al., 2001; Kousteni et al., 
TABLE 1 
Tissue specificity for the effect of estren compared with the effect of 
17/3-estradiol on uterine weight, gonadal fat weight, thymus weight, 
trabecular BMD, and cortical BMC 
Eleven-month-old female mice w ere ovariectomized and then treated for 4 weeks 
with vehicle, 17/3-estradiol, or estren (n = 8). Values for the effect of estren compared 
with the effect of 17/3-estradiol are given as the effect of estren divided by the effect 
of 17/3-estradiol and are expressed as a percentage (equal to the percentage of 
estrogenic activity of estren) and as the relative tissue specificity for the estrogenic 
activity of estren when the effect on uterus is given as 1 (equal to the relative tissue 
specificity of estren). 
Parameter Estrogenic Activity of Relative Tissue Specificity of Estren Estren (Uterus = 1) 
Uterine weight 
% 
16.2 1 
Gonadal fat weight 0 0 
Thymus weight 71 4.4 
Trabecular BMD 21.8 1.3 
Cortical BMC 0 0 
2001). The recently described extranuclear mode of action of 
estren in bone has led to the definition of a novel class of 
mechanism-specific substances called ANGELS (Activator of 
NonGenotropic Estrogen-Like Signaling) (Manolagas et al., 
2002). However, the present study indicates that estren 
rather, in a wider perspective, is a SERM with transcrip­
tional activity. 
The results of our present characterization of the effects of 
estren are in conflict with two previous publications from one 
research group describing the in vitro and in vivo effects of 
estren (Kousteni et al., 2001, 2002). In the in vivo study by 
Kousteni et al., it was found that estren had no effect on the 
uterine weight, whereas in the present study, using even a 
slightly lower dose of es tren than in the previous study, a 
clear estren-induced increase in uterine weight was seen. In 
agreement with the previous study, the amount of trabecular 
bone was increased by estren in the present study. However, 
I I vehicle 
Oil 17ß-estradiol 
• estren A. 140 
Li> 
WT ERor'ß'-
B. 140-
120-
T 
100- Ï 
O) 
00
 
0
 
o
 
1 
1 
** 1 
40- • 
20- 1 
n u -
WT ERcr'-ß-'-
Fig. 2. Weight of gonadal (A) and retroperitoneal (B) fat deposits. Eleven-
month-old female WT and ER« ' ß 7 mice were ovariectomized and 
then treated with vehicle, 17ß-estradiol (0.7 /xg/mouse/day), or estren (75 
jig/mouse/day) for 4 weeks (/i = 8). Values are given as means ± S .E.M. 
**,p < 0.01, ***,p < 0.001 versus vehicle, Student's t. tes t followed by 
post hoc analysis according to Bonferroni test. 
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in our study, the estrogen-like activity of estren was of the 
same magnitude on uterus as on trabecular bone, whereas in 
the previous study, a clear effect was seen on bone without 
any effect on uterus. It is difficult to explain the different 
results of the two studies. One may speculate that the 60-day 
slow-release treatment in the previous study was active dur­
ing most of the time but not during the last few days of 
treatment. This would then result in bone, a slow-responding 
tissue, being preserved, with the uterus, a fast-responding 
tissue, no longer showing any effects of estren at the end of 
the treatment period. In contrast, in the present study, es­
tren was given as subcutaneous daily injections during the 
whole experiment to ensure that the animals received the 
treatment until the final analysis. 
In the present study, the effect of estren on several differ­
ent tissues was investigated and compared with the effect of 
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Fig. 3. A, trabecular volumetric BMD of the metaphyseal area of the 
proximal tibia measured using pQCT. B, cortical BMC as determined 
using a mid-diaphyseal pQCT scan of t he femur. Eleven-month-old fe­
male WT and ER« mice were ovariectomized and then treated 
with vehicle, 17/3-estradiol (0.7 jxg/mouse/day), or estren (75 /xg/mouse/ 
day) for 4 weeks (n = 8). Values are given as means ± S.E.M. **,p < 0.01, 
*p < 0.05 versus vehicle, Student's t test followed by post hoc analysis 
according to Bonferroni test. 
17/3-estradiol. It was demonstrated that estren exerts a rel­
atively strong effect on thymus weight, a medium effect on 
uterus weight and trabecular bone, and no effect on fat mass 
or cortical bone. Thus, the degree of the estrogen-like activity 
of estren is tissue-specific. 
Previous in vitro data have indicated that the effect of 
estren might be mediated via ERs or the AR with similar 
efficiency (Kousteni et al., 2001, 2002). Here, we demonstrate 
in vivo that the effects of estren on trabecular bone and 
uterus are mediated via ERs and that the AR cannot replace 
the ERs in mediating these effects. We also demonstrate that 
the trabecular bone-sparing effect of 17ß-estradiol is medi­
ated only via ERs and not via the AR. Furthermore, the 
bone-sparing effect of 5a-dihydrotestosterone-induced AR 
stimulation is not dependent on the ERs (Movérare et al., 
2003). Therefore, in contrast to what has recently been con­
cluded from in vitro studies (Kousteni et al., 2001), there is no 
cross-reactivity between ERs and AR for the mediation of the 
trabecular bone-sparing effect of sex steroids, and the effect 
of e stren in vivo i s only mediated via ERs. Unfortunately, 
because of a complex breeding procedure of t he ER-inacti-
vated mice, no sham-operated control group was included in 
the present study. However, we have in a previous study seen 
that the 17ß-estradiol dose given to the ovx mice in the 
present study results in sham-operated control levels for the 
different estrogen-responsive parameters analyzed in the 
present study (data not shown). 
Because of an in vitro finding that estren did not induce C3 
transcription in ERa-transfected HeLa cells, it was postu­
lated that estren has no transcriptional activity and that all 
of its effects must be nongenomic (Kousteni et al., 2001). In 
contrast, using another well-established in vitro system of 
human 293 kidney epithelial ERa- and ERß-expressing re­
porter cell lines (Barkhem et al., 1998), we demonstrated 
that estren displays a full agonistic effect on transcriptional 
activity with a degree of agonism similar to that of 17/3-
estradiol for both ERa and ER/3. The specificity of this effect 
was confirmed by the result that the ER antagonist ICI 
182,780 antagonized, in a dose-dependent manner, the effect 
of e stren on the transcriptional activity mediated via both 
receptors. Thus, estren has the capacity to exert genomic 
effects via both ERa and ER/3. I n addition, we have also 
monitored the genomic response to estren in the human 
endometrial carcinoma cell l ine Ishikawa (Littlefield et al., 
1990) by analyzing the expression of the endogenous alkaline 
phosphatase gene. Similar to the response in the genetically 
engineered 293 ERa and ER/3 reporter cell lines, estren gen­
erated an agonist response that was totally blunted by the 
pure ER antagonist ICI 182,780 (data not shown), supporting 
the notion that estren exerts ER-mediated genomic effects. 
The conflicting results in the previous study using HeLa 
cells compared with the present study using 293 kidney 
epithelial cells might depend on the choice of promoter and/or 
the choice of cell line. It is well known that the effect of ERs 
is exclusively mediated via AF-2 in HeLa cells (Berry et al., 
1990; Metivier et al., 2000), whereas in the 293 kidney epi­
thelial cells, the activity of the ERs is dependent on the 
function of bo th AF-1 and AF-2. The lack of transcriptional 
activity of estren in HeLa cells might indicate that the ago­
nist effect of estren on ERs requires functionality of both 
AF-1 and AF-2 (Berry et al., 1990; Metivier et al., 2000). We 
do not doubt that estren, in analogy to 17/3-estradiol, also 
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Fig. 4. Effect of estren and 17/3-estradiol on transcriptional activity. Response to increasing concentrations of 17ß-estradiol and estren in the 293/hERa 
(A) and 293/hERß (B) reporter cell lines. The level of ALP reporter protein expressed was analyzed 72 h after the addition of the ligands. Antagonist 
response to increasing concentration of ICI 182,780 in the presence or absence of estren (100 nM) in 293/hERa (C) and 293/hERß (D) reporter cell lines. 
The response values for each concentration of ligand are the means of triplicate determinations with the means ± S.D. for each value indicated. 
elicits nongenomic responses, but our data clearly indicate, 
in contrast to the data from the study by Kousteni et al. 
(2002), that estren also has typical genomic effects. Thus, our 
data suggest that the biological effect of estren cannot solely 
be explained by a nongenomic mechanism but that genomic 
mechanisms of estren also have to be considered. 
In conclusion, our results demonstrate that estren is a 
SERM with effects on uterus, trabecular bone, and thymus 
but without major effect on fat or cortical bone. The effects of 
estren on bone and uterus are mediated via ERs, and the AR 
cannot replace the ERs for these effects. Furthermore, it is 
clear that estren has the capacity to exert genomic effects 
mediated via ERs. 
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